

09890219

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1612bxr

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAPLUS patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the EPOLINE Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAPLUS currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances
NEWS EXPRESS	JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.		

Updated Search

09890219

NEWS HOURS      STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN      Welcome Banner and News Items  
NEWS IPC8        For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 17:23:26 ON 03 NOV 2008

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 03 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES:    2 NOV 2008    HIGHEST RN 1070028-20-4  
DICTIONARY FILE UPDATES:   2 NOV 2008    HIGHEST RN 1070028-20-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Documents and Settings\brobinson1\My Documents\nhgt.str

L1            STRUCTURE UPLOADED

=> s l1  
SAMPLE SEARCH INITIATED 17:26:55 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED -    23379 TO ITERATE

Updated Search

09890219

8.6% PROCESSED 2000 ITERATIONS 5 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 458428 TO 476732  
PROJECTED ANSWERS: 710 TO 1626

L2 5 SEA SSS SAM L1

=> s l1 full  
THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y  
FULL SEARCH INITIATED 17:27:10 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 470260 TO ITERATE

98.7% PROCESSED 464013 ITERATIONS 728 ANSWERS

100.0% PROCESSED 470260 ITERATIONS 728 ANSWERS  
SEARCH TIME: 00.00.20

L3 728 SEA SSS FUL L1

=> file hcaplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 181.12 181.33

FILE 'HCAPLUS' ENTERED AT 17:27:38 ON 03 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Nov 2008 VOL 149 ISS 19  
FILE LAST UPDATED: 2 Nov 2008 (20081102/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Updated Search

$\Rightarrow$  s 13

=> file req

SINCE FILE

ENTRY

## SESSION

2.69

184.02

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

DICTIONARY FILE UPDATES: 2 NOV 2008 HIGHEST BN 1070028-20-4

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

 $\Rightarrow$ 

Uploading C:\Documents and Settings\brobinson1\My Documents\jnh.str

L5 STRUCTURE UPLOADED

$\Rightarrow$  S 15

SAMPLE SEARCH INITIATED 17:32:02 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 23379 TO ITERATE

```

8.6% PROCESSED      2000 ITERATIONS                      4 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

```

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH       \*\*COMPLETE\*\*

PROJECTED ITERATIONS:           458428 TO       476732

PROJECTED ANSWERS: 525 TO 1345

L6                      4 SEA SSS SAM L5

=> s 15 full

THE ESTIMATED SEARCH COST FOR FILE 'REGISTRY' IS 177.90 U.S. DOLLARS  
DO YOU WANT TO CONTINUE WITH THIS REQUEST? (Y)/N or END:y

Updated Search

09890219

FULL SEARCH INITIATED 17:32:06 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 470260 TO ITERATE

98.6% PROCESSED 463875 ITERATIONS 700 ANSWERS

100.0% PROCESSED 470260 ITERATIONS 700 ANSWERS  
SEARCH TIME: 00.00.20

L7 700 SEA SSS FUL L5

=> d his

(FILE 'HOME' ENTERED AT 17:23:26 ON 03 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 03 NOV 2008

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 728 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:27:38 ON 03 NOV 2008

L4 47 S L3

FILE 'REGISTRY' ENTERED AT 17:27:44 ON 03 NOV 2008

L5 STRUCTURE UPLOADED

L6 4 S L5

L7 700 S L5 FULL

=> s 17 not 13

L8 0 L7 NOT L3

=> file hcaplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	182.04	366.06

FILE 'HCAPLUS' ENTERED AT 17:33:10 ON 03 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Nov 2008 VOL 149 ISS 19  
FILE LAST UPDATED: 2 Nov 2008 (20081102/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Updated Search

09890219

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 17

L9 41 L7

=> s 19 and matsuoka, h?/au

2774 MATSUOKA, H?/AU

L10 3 L9 AND MATSUOKA, H?/AU

=> d l10, ibib abs hitstr, 1-3

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:157810 HCAPLUS

DOCUMENT NUMBER: 136:217049

TITLE: Preparation of cyclic peptide derivatives as motilin receptor antagonists

INVENTOR(S): Matsuoka, Hiroharu; Sato, Tsutomu

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 89 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002016404	A1	20020228	WO 2001-JP7213	20010823
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2001080120	A	20020304	AU 2001-80120	20010823
EP 1312612	A1	20030521	EP 2001-958426	20010823
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
US 20030191053	A1	20031009	US 2003-362574	20030224
US 7018981	B2	20060328		
PRIORITY APPLN. INFO.:			JP 2000-253950	A 20000824
			WO 2001-JP7213	W 20010823
OTHER SOURCE(S):	MARPAT 136:217049			
GI				

Updated Search



AB The title compds. I [T1 = (CH<sub>2</sub>)<sub>m</sub>; T2 = (CH<sub>2</sub>)<sub>n</sub>; R1 represents optionally substituted Ph, etc.; R2 represents amino, etc.; R3 to R6 each represents hydrogen, Me, etc.; V, W, X, Y, Z represent carbonyl or methylene; m is an integer of 0 to 2; and n is an integer of 0 to 3] are prepared In an in vitro test for motilin receptor antagonism, (2S-(2S,12S))-2-amino-N-(2-(3-tert-butyl-4-hydroxyphenylmethyl)-1,4,8-triaza-3,7,13-trioxocyclotridecan-12-yl)-3-(4-fluorophenyl)-N-methylpropionamide showed IC<sub>50</sub> of 0.52 nM.

IT 401896-11-5P 401896-12-6P 401896-13-7P  
 401896-15-9P 401896-25-1P 401896-27-3P  
 401896-29-5P 401896-30-8P 401896-32-0P  
 401896-35-3P 401896-36-4P 401896-37-5P  
 401896-39-7P 401896-41-1P 401896-42-2P  
 401896-43-3P 401896-45-5P 401896-48-8P  
 401896-49-9P 401896-50-2P 401896-52-4P  
 401896-55-7P 401896-58-0P 401896-59-1P  
 401896-60-4P 401896-61-5P 401896-62-6P  
 401896-63-7P 401896-64-8P 401896-65-9P  
 401896-68-2P 401896-69-3P 401896-70-6P  
 401896-72-8P 401896-73-9P 401896-74-0P  
 401896-76-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of cyclic peptide derivs. as motilin receptor antagonists)

RN 401896-11-5 HCAPLUS

CN β-Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


09890219



RN 401896-12-6 HCAPLUS

CN  $\beta$ -Alanine, N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-13-7 HCAPLUS

CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search



09890219


RN 401896-15-9 HCAPLUS  
CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401896-25-1 HCAPLUS  
CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-N-methyl-L-tyrosyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




RN 401896-27-3 HCAPLUS  
CN Glycine, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-  
[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-,  
phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-29-5 HCAPLUS

CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-30-8 HCAPLUS

CN Glycine, N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 401896-32-0 HCAPLUS  
CN Glycine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401896-35-3 HCAPLUS  
CN  $\beta$ -Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-36-4 HCAPLUS  
CN  $\beta$ -Alanine, N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-37-5 HCAPLUS

CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-N-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-39-7 HCAPLUS

CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-41-1 HCAPLUS

CN  $\beta$ -Alanine, N2-[(1,1-dimethylethoxy)carbonyl]-N2,N6-dimethyl-N6-  
[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-,  
phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-42-2 HCAPLUS

CN  $\beta$ -Alanine, N2,N6-dimethyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-  
dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-43-3 HCAPLUS

Updated Search

09890219

CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2,N6-dimethyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-45-5 HCAPLUS

CN  $\beta$ -Alanine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2,N6-dimethyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-48-8 HCAPLUS

CN L-Tyrosinamide, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-N-[4-oxo-4-(phenylmethoxy)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-49-9 HCAPLUS

CN L-Tyrosinamide, N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-N-[4-oxo-4-(phenylmethoxy)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-50-2 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-N-[4-oxo-4-(phenylmethoxy)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 401896-52-4 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2-methyl-L-lysyl-N-(3-carboxypropyl)-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401896-55-7 HCAPLUS  
CN  $\beta$ -Alanine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-58-0 HCAPLUS  
CN L-Tyrosine, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-[(phenylmethoxy)carbonyl]-L-lysyl-3-(1,1-dimethylethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 401896-59-1 HCAPLUS

CN L-Tyrosine, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-60-4 HCAPLUS

CN L-Tyrosine, N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-[3-[[ (phenylmethoxy)carbonyl]amino]propyl]-L-lysyl-3-(1,1-dimethylethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-61-5 HCAPLUS

Updated Search

09890219

CN L-Tyrosine, N6-acetyl-N2-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-N6-[3-  
[[ (phenylmethoxy)carbonyl]amino]propyl]-L-lysyl-3-(1,1-dimethylethyl)-,  
methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-62-6 HCAPLUS

CN L-Tyrosine, N6-acetyl-N2-methyl-N6-[3-  
[[ (phenylmethoxy)carbonyl]amino]propyl]-L-lysyl-3-(1,1-dimethylethyl)-,  
methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-63-7 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N6-  
acetyl-N2-methyl-N6-[3-[[ (phenylmethoxy)carbonyl]amino]propyl]-L-lysyl-3-  
(1,1-dimethylethyl)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-64-8 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N6-acetyl-N6-(3-aminopropyl)-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 401896-65-9 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N6-acetyl-N2-methyl-N6-[3-[[ (phenylmethoxy)carbonyl]amino]propyl]-L-lysyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-68-2 HCAPLUS

CN L-Tyrosinamide, N2-[(1,1-dimethylethoxy)carbonyl]-N2,N5-dimethyl-N5-[(phenylmethoxy)carbonyl]-L-ornithyl-3-(1,1-dimethylethyl)-N-[4-oxo-4-(phenylmethoxy)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401896-69-3 HCAPLUS

CN L-Tyrosinamide, N2,N5-dimethyl-N5-[(phenylmethoxy)carbonyl]-L-ornithyl-3-(1,1-dimethylethyl)-N-[4-oxo-4-(phenylmethoxy)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 401896-70-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N2,N5-dimethyl-N5-[(phenylmethoxy)carbonyl]-L-ornithyl-3-(1,1-dimethylethyl)-N-[4-oxo-4-(phenylmethoxy)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401896-72-8 HCAPLUS  
CN  $\beta$ -Alanine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-73-9 HCAPLUS  
CN  $\beta$ -Alanine, N6-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 401896-74-0 HCAPLUS

CN  $\beta$ -Alanine, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N6-[(1,1-dimethylethoxy)carbonyl]-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401896-76-2 HCAPLUS

CN  $\beta$ -Alanine, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N2-methyl-L-lysyl-3-(1,1-dimethylethyl)-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

09890219



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:535162 HCAPLUS

DOCUMENT NUMBER: 133:150920

TITLE: Preparation of peptides or analogs containing substituted phenethylamine moiety as motilin receptor antagonists

INVENTOR(S): Matsuoka, Hiroharu; Sato, Tsutomu; Takahashi, Tadakatsu; Kim, Dong Ick; Jung, Kyung Yun; Park, Chan Hee

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 403 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044770	A1	20000803	WO 2000-JP444	20000128
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2359030	A1	20000803	CA 2000-2359030	20000128
EP 1149843	A1	20011031	EP 2000-901956	20000128
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
HU 2001005204	A2	20020429	HU 2001-5204	20000128
HU 2001005204	A3	20020528		
JP 3715202	B2	20051109	JP 2000-596026	20000128
NO 2001003684	A	20010928	NO 2001-3684	20010726

Updated Search





09890219

287206-13-7P 287206-14-8P 287206-15-9P  
287206-16-0P 287206-17-1P 287206-18-2P  
287206-19-3P 287206-20-6P 287206-21-7P  
287206-22-8P 287206-23-9P 287206-24-0P  
287206-25-1P 287206-26-2P 287206-27-3P  
287206-28-4P 287206-29-5P 287206-30-8P  
287206-31-9P 287206-32-0P 287206-33-1P  
287206-34-2P 287206-35-3P 287206-36-4P  
287206-37-5P 287206-38-6P 287206-39-7P  
287206-40-0P 287206-41-1P 287206-42-2P  
287206-43-3P 287206-44-4P 287206-45-5P  
287206-46-6P 287206-47-7P 287206-49-9P  
287206-50-2P 287206-51-3P 287206-52-4P  
287206-53-5P 287206-55-7P 287206-56-8P  
287206-58-0P 287206-59-1P 287206-60-4P  
287206-61-5P 287206-62-6P 287206-63-7P  
287206-64-8P 287206-65-9P 287206-66-0P  
287206-67-1P 287206-68-2P 287206-69-3P  
287206-70-6P 287206-71-7P 287206-72-8P  
287206-73-9P 287206-74-0P 287206-75-1P  
287206-76-2P 287206-77-3P 287206-78-4P  
287206-79-5P 287206-80-8P 287206-81-9P  
287206-82-0P 287206-83-1P 287206-84-2P  
287206-85-3P 287206-86-4P 287206-87-5P  
287206-88-6P 287206-89-7P 287206-90-0P  
287206-91-1P 287206-92-2P 287206-93-3P  
287206-94-4P 287206-95-5P 287206-96-6P  
287206-97-7P 287206-98-8P 287206-99-9P  
287207-00-5P 287207-01-6P 287207-02-7P  
287207-03-8P 287207-04-9P 287207-05-0P  
287207-06-1P 287207-07-2P 287207-08-3P  
287207-09-4P 287207-12-9P 287207-13-0P  
287207-14-1P 287207-15-2P 287207-16-3P  
287207-17-4P 287207-18-5P 287207-19-6P  
287207-20-9P 287207-21-0P 287207-22-1P  
287207-23-2P 287207-24-3P 287207-26-5P  
287207-27-6P 287207-28-7P 287207-29-8P  
287207-30-1P 287207-33-4P 287207-34-5P  
287207-36-7P 287207-37-8P 287207-38-9P  
287207-39-0P 287207-40-3P 287207-41-4P  
287207-42-5P 287209-74-9P 287209-77-2P  
287211-41-0P 287212-48-0P 287212-51-5P  
287212-55-9P 287212-56-0P 287212-57-1P  
287212-58-2P 287212-59-3P 287212-60-6P  
287212-61-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of peptides or analogs containing substituted phenethylamine moiety

as motilin receptor antagonists and drugs for preventing digestive tract movement or high level of blood motilin)


RN 287205-81-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287205-82-7 HCAPLUS

CN L-Tyrosinamide, 4-chloro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287205-83-8 HCAPLUS

CN L-Tyrosinamide, 3,4-difluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287205-84-9 HCAPLUS

CN L-Tyrosinamide, 3-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287205-85-0 HCAPLUS

CN L-Tyrosinamide, 2-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

09890219




RN 287205-87-2 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl-N-(methylsulfonyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 287205-86-1  
CMF C30 H43 F N4 O6 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 287205-88-3 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-

Updated Search

09890219

dimethylethyl)-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287205-89-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287205-90-7 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-2-[(aminocarbonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287205-91-8 HCAPLUS  
CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-2-[(aminoiminomethyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 287205-92-9 HCAPLUS  
CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-2-[[[(cyanoamino)(methylamino)methylene]amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287205-93-0 HCAPLUS  
CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-2-[(aminosulfonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287205-94-1 HCAPLUS

CN Glycinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-L-tyrosyl-ψ(CH<sub>2</sub>-NH)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287205-95-2 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[(methylsulfonyl)amino]ethyl]-N<sub>2</sub>-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287205-96-3 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-3-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-3-oxopropyl]-N<sub>2</sub>-methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287205-97-4 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methylsulfonyl)ethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287205-98-5 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287205-99-6 HCAPLUS


CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]amino]-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methylsulfonyl)ethyl]-3-methyl-, (2S)- (CA INDEX NAME)

Updated Search



09890219


Absolute stereochemistry.



RN 287206-07-9 HCAPLUS

CN L-Tyrosinamide, 2-fluoro-L-tyrosyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-08-0 HCAPLUS

CN L-Tyrosinamide, 3-fluoro-L-tyrosyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-09-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-10-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-11-5 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-12-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-13-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287206-14-8 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-15-9 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-16-0 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,α-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-17-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,Nα-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287206-18-2 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-19-3 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-20-6 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-21-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-22-8 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-23-9 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287206-24-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-25-1 HCAPLUS


CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287206-26-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-27-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-28-4 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287206-29-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-30-8 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-31-9 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-32-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219

RN 287206-33-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-34-2 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-35-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-36-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,α-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-37-5 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,α-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287206-38-6 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-39-7 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-40-0 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-41-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-42-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287206-43-3 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-44-4 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-N,3-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-45-5 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search



09890219


RN 287206-46-6 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-2-amino-3-(4-fluorophenyl)propyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-47-7 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-2-amino-3-(4-fluorophenyl)propyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-49-9 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-2-amino-3-(4-fluorophenyl)propyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-50-2 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]amino]-N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-3-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-51-3 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]methylamino]-N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-52-4 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]amino]-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,3-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-53-5 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]methylamino]-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,3-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-55-7 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]amino]-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-56-8 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]methylamino]-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-58-0 HCAPLUS

CN Butanamide, 2-[[[(2S)-2-amino-3-(4-fluorophenyl)propyl]methylamino]-N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-N,3-dimethyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-59-1 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-2-amino-3-(4-fluorophenyl)propyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-60-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-61-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-62-6 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287206-63-7 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-64-8 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-65-9 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-66-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-67-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN	287206-68-2	HCAPLUS
CN	L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,Nα-diethyl- (9CI) (CA INDEX NAME)	

CCN(C)C(=O)SCC1=CC=C(C=C1)C(=O)NCC

Absolute stereochemistry.




Absolute stereochemistry.

Updated Search




09890219



RN 287206-71-7 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-72-8 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287206-73-9 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-74-0 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-75-1 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-76-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,  $\alpha$ -diethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-77-3 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,  $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287206-78-4 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-79-5 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-80-8 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-N-cyclopropyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-81-9 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-

Updated Search

09890219

dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-82-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-83-1 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-84-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-85-3 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-86-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-87-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-88-6 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-89-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-90-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-91-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-92-2 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(4-morpholinyl)-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287206-93-3 HCAPLUS


CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[4-(methylsulfonyl)-1-piperazinyl]-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287206-94-4 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[4-(2-ethoxy-2-oxoethyl)-1-piperazinyl]-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-95-5 HCAPLUS

CN L-Valinamide, 4-fluoro-L-phenylalanyl-N-[(1S)-2-[4-(carboxymethyl)-1-piperazinyl]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287206-96-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287206-97-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-(2S)-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287206-98-8 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-(2R)-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287206-99-9 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-00-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-D-norvalyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-01-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-isoleucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-02-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-D-isoleucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287207-03-8 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-leucyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-04-9 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-D-leucyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-05-0 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-4,5-didehydro-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-06-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-4,5-didehydro-N-methyl-D-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-07-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,4-dimethyl-L-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287207-08-3 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,4-dimethyl-D-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-09-4 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-(2S)-4,4,4-trifluoro-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-12-9 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-3-cyclohexyl-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-13-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-3-cyclohexyl-N-methyl-D-alanyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-14-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search




09890219

RN 287207-15-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-16-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-4-fluoro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-17-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-4-fluoro-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-18-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-4-chloro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-19-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-4-chloro-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-20-9 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-tyrosyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-21-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-D-tyrosyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-22-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-3-(2-thienyl)-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-23-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-3-(2-thienyl)-D-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-24-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-3-cyclopropyl-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-26-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,α-dimethyl-L-phenylalanyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-27-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,α-dimethyl-D-phenylalanyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-28-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,2-dimethyl-L-leucyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-29-8 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-30-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,3-dimethyl-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-33-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,3-dimethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-34-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N,3-dimethyl-L-valyl-3-(1,1-dimethylethyl)-N- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-36-7 HCAPLUS

CN L-Tyrosinamide, 3-(2-fluoro-4-pyridinyl)-L-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-37-8 HCAPLUS


CN L-Tyrosinamide, 3-(6-fluoro-3-pyridinyl)-L-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287207-38-9 HCAPLUS

CN L-Tyrosinamide, 4-(trifluoromethyl)-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-39-0 HCAPLUS

CN L-Tyrosinamide, N-[(2R)-3-(4-fluorophenyl)-2-(hydroxymethyl)-1-oxopropyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287207-40-3 HCAPLUS  
CN L-Tyrosinamide, 3-(4-pyridinyl)-L-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-41-4 HCAPLUS  
CN L-Tyrosinamide, 4-cyano-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-42-5 HCAPLUS  
CN L-Tyrosinamide, L-tryptophyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-74-9 HCAPLUS

CN Butanamide, 2-[[[(2R)-2-amino-3-(4-fluorophenyl)propyl]amino]-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-3-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-77-2 HCAPLUS

CN Butanamide, 2-[[[(2R)-2-amino-3-(4-fluorophenyl)propyl]methylamino]-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-41-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-(2R)-4,4,4-trifluoro-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287212-48-0 HCAPLUS

CN L-Tyrosinamide, 3-(2-fluoro-4-pyridinyl)-D-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287212-51-5 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-3-(4-fluorophenyl)-2-(hydroxymethyl)-1-oxopropyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219




RN 287212-55-9 HCAPLUS

CN Tyrosinamide, 4-fluorophenylalanyl-N-methylvalyl-3-(1,1-dimethylethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)



RN 287212-56-0 HCAPLUS

CN Valinamide, N-(4-fluorophenyl)alanyl-N-[2-[(aminocarbonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)




RN 287212-57-1 HCAPLUS

CN Valinamide, N-(4-fluorophenyl)alanyl-N-[2-[(aminosulfonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Updated Search

09890219




RN 287212-58-2 HCAPLUS  
 CN Valinamide, 4-fluoro-L-phenylalanyl-N-[1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[(methylsulfonyl)amino]ethyl]-N2-methyl- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 287212-59-3 HCAPLUS  
 CN Valinamide, N-(4-fluorophenyl)alanyl-N-[3-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-3-oxopropyl]-N2-methyl- (9CI) (CA INDEX NAME)



RN 287212-60-6 HCAPLUS  
 CN Valinamide, N-(4-fluorophenyl)alanyl-N-[1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methylsulfonyl)ethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Updated Search

09890219



RN 287212-61-7 HCAPLUS

CN Valinamide, N-(4-fluorophenyl)alanyl-N-[2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-N2-methyl- (9CI) (CA INDEX NAME)



IT 220808-01-5P 220808-37-7P 220808-45-7P  
220808-87-7P 220808-88-8P 287207-47-0P  
287207-48-1P 287207-49-2P 287207-50-5P  
287207-51-6P 287207-53-8P 287207-55-0P  
287207-56-1P 287207-59-4P 287207-60-7P  
287207-61-8P 287207-64-1P 287207-65-2P  
287207-66-3P 287207-70-9P 287207-72-1P  
287207-73-2P 287207-75-4P 287207-78-7P  
287207-79-8P 287207-81-2P 287207-82-3P  
287207-84-5P 287207-86-7P 287207-88-9P  
287207-90-3P 287207-95-8P 287207-98-1P  
287208-05-3P 287208-06-4P 287208-07-5P  
287208-12-2P 287208-13-3P 287208-15-5P  
287208-16-6P 287208-17-7P 287208-18-8P  
287208-20-2P 287208-21-3P 287208-45-1P  
287208-74-6P 287208-75-7P 287208-93-9P  
287208-94-0P 287208-95-1P 287208-96-2P  
287208-97-3P 287208-98-4P 287208-99-5P  
287209-00-1P 287209-01-2P 287209-02-3P  
287209-03-4P 287209-04-5P 287209-05-6P  
287209-06-7P 287209-07-8P 287209-08-9P  
287209-09-0P 287209-10-3P 287209-11-4P  
287209-12-5P 287209-13-6P 287209-14-7P  
287209-15-8P 287209-16-9P 287209-17-0P  
287209-18-1P 287209-19-2P 287209-20-5P  
287209-21-6P 287209-22-7P 287209-23-8P  
287209-24-9P 287209-25-0P 287209-26-1P  
287209-27-2P 287209-28-3P 287209-29-4P  
287209-30-7P 287209-31-8P 287209-32-9P  
287209-33-0P 287209-34-1P 287209-35-2P  
287209-36-3P 287209-37-4P 287209-38-5P  
287209-39-6P 287209-40-9P 287209-41-0P

Updated Search

09890219

287209-42-1P 287209-43-2P 287209-44-3P  
287209-45-4P 287209-46-5P 287209-47-6P  
287209-48-7P 287209-49-8P 287209-50-1P  
287209-51-2P 287209-52-3P 287209-53-4P  
287209-54-5P 287209-55-6P 287209-58-9P  
287209-59-0P 287209-60-3P 287209-61-4P  
287209-62-5P 287209-63-6P 287209-64-7P  
287209-65-8P 287209-66-9P 287209-67-0P  
287209-68-1P 287209-71-6P 287209-72-7P  
287209-73-8P 287209-75-0P 287209-76-1P  
287209-80-7P 287209-81-8P 287209-82-9P  
287209-83-0P 287209-84-1P 287209-85-2P  
287209-86-3P 287210-07-5P 287210-08-6P  
287210-09-7P 287210-10-0P 287210-11-1P  
287210-12-2P 287210-13-3P 287210-14-4P  
287210-15-5P 287210-16-6P 287210-17-7P  
287210-18-8P 287210-19-9P 287210-20-2P  
287210-21-3P 287210-22-4P 287210-23-5P  
287210-24-6P 287210-25-7P 287210-26-8P  
287210-27-9P 287210-28-0P 287210-29-1P  
287210-30-4P 287210-31-5P 287210-32-6P  
287210-33-7P 287210-34-8P 287210-35-9P  
287210-36-0P 287210-37-1P 287210-38-2P  
287210-39-3P 287210-40-6P 287210-41-7P  
287210-42-8P 287210-43-9P 287210-44-0P  
287210-45-1P 287210-46-2P 287210-47-3P  
287210-48-4P 287210-49-5P 287210-50-8P  
287210-51-9P 287210-52-0P 287210-53-1P  
287210-54-2P 287210-55-3P 287210-56-4P  
287210-57-5P 287210-58-6P 287210-59-7P  
287210-60-0P 287210-61-1P 287210-62-2P  
287210-63-3P 287210-64-4P 287210-65-5P  
287210-66-6P 287210-67-7P 287210-68-8P  
287210-69-9P 287210-70-2P 287210-71-3P  
287210-72-4P 287210-73-5P 287210-74-6P  
287210-75-7P 287210-76-8P 287210-79-1P  
287211-00-1P 287211-01-2P 287211-02-3P  
287211-03-4P 287211-04-5P 287211-05-6P  
287211-06-7P 287211-07-8P 287211-08-9P  
287211-09-0P 287211-10-3P 287211-11-4P  
287211-12-5P 287211-13-6P 287211-14-7P  
287211-15-8P 287211-16-9P 287211-17-0P  
287211-18-1P 287211-19-2P 287211-21-6P  
287211-22-7P 287211-23-8P 287211-24-9P  
287211-25-0P 287211-26-1P 287211-27-2P  
287211-28-3P 287211-29-4P 287211-30-7P  
287211-31-8P 287211-32-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of peptides or analogs containing substituted phenethylamine  
moiety

as motilin receptor antagonists and drugs for preventing digestive  
tract movement or high level of blood motilin)

RN 220808-01-5 HCAPLUS


CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-  
dimethylethyl)- (9CI) (CA INDEX NAME)

Updated Search



09890219


Absolute stereochemistry.



RN 220808-37-7 HCAPLUS

CN	L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI)	(CA INDEX NAME)
----	---	-----------------


Absolute stereochemistry.



RN 220808-45-7 HCAPLUS

CN L-Tyrosinamide, L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-87-7 HCAPLUS

Updated Search

09890219

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-88-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-47-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-48-1 HCAPLUS

CN L-Tyrosinamide, 4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-49-2 HCAPLUS

CN L-Tyrosinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3,4-difluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-50-5 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-51-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-53-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-55-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219

RN 287207-56-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-59-4 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-methoxy-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-60-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methoxy-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-61-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methoxy-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-64-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-65-2 HCAPLUS


CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-2-pyridinyl-

Updated Search

09890219

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-66-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-2-pyridinyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-70-9 HCAPLUS


CN Carbamic acid, [(1S)-1-[[[(1S)-2-[(aminocarbonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]amino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219




RN 287207-72-1 HCAPLUS  
CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
[(1S)-2-[(aminocarbonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-  
hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-73-2 HCAPLUS  
CN Butanamide, N-[(1S)-2-[(aminocarbonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-  
hydroxyphenyl]methyl]ethyl]-3-methyl-2-(methylamino)-, (2S)- (CA INDEX  
NAME)

Absolute stereochemistry.




RN 287207-75-4 HCAPLUS  
CN 10-Oxa-2,5,8-triazadodecanoic acid,

Updated Search

09890219

6-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2,11,11-trimethyl-3-(1-methylethyl)-4,9-dioxo-, phenylmethyl ester, (3S,6S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-78-7 HCAPLUS

CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-79-8 HCAPLUS

CN Carbamic acid, [(2S)-3-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-2-[[[(2S)-3-methyl-2-(methylamino)-1-oxobutyl]amino]propyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-81-2 HCAPLUS

CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-2-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-82-3 HCAPLUS

CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-2-[(aminoiminomethyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219

RN 287207-84-5 HCAPLUS

CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-2-[[ (cyanoamino) (methylamino)methylene]amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-86-7 HCAPLUS

CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-2-[(aminosulfonyl)amino]-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287207-88-9 HCAPLUS

CN Glycine, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-L-tyrosyl-ψ(CH<sub>2</sub>-NH)-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287207-90-3 HCAPLUS

CN Glycinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-L-tyrosyl-ψ(CH<sub>2</sub>-NH)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287207-95-8 HCAPLUS

CN 9-Thia-2,5,8-triazadecanoic acid, 6-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-methyl-3-(1-methylethyl)-4-oxo-, phenylmethyl ester, 9,9-dioxide, (3S,6S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 287207-98-1 HCAPLUS


CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-

Updated Search

09890219

1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-  
[(methylsulfonyl)amino]ethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287208-05-3 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-3-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-3-oxopropyl]amino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287208-06-4 HCAPLUS

CN Benzenebutanamide, 3-(1,1-dimethylethyl)-4-hydroxy-β-[[[(2S)-3-methyl-2-(methylamino)-1-oxobutyl]amino]-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287208-07-5 HCAPLUS  
CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-3-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-3-oxopropyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287208-12-2 HCAPLUS  
CN Carbamic acid, [(1S)-1-[[[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methanesulfonyl)ethyl]amino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287208-13-3 HCAPLUS  
CN L-Valinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methanesulfonyl)ethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287208-15-5 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]amino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287208-16-6 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-N2-  
methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287208-17-7 HCAPLUS


CN Butanamide, N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-3-methyl-2-(methylamino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287208-18-8 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methylsulfonyl)ethyl]amino]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287208-20-2 HCAPLUS

CN 11-Thia-2,5,8-triazadodecanoic acid, 9-[[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-3-[(4-fluorophenyl)methyl]-6-(1-methylethyl)-7-oxo-, 1,1-dimethylethyl ester, 11,11-dioxide, (3S,6S,9S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 287208-21-3 HCAPLUS

CN Butanamide, 2-amino-N-[(1S)-1-[[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(methylsulfonyl)ethyl]-3-methyl-, (2S)- (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287208-45-1 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287208-74-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-2-fluoro-L-tyrosyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287208-75-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-fluoro-L-tyrosyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287208-93-9 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287208-94-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287208-95-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287208-96-2 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 287208-97-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287208-98-4 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287208-99-5 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-00-1 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-01-2 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287209-02-3 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-03-4 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-04-5 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




Updated Search



09890219


RN 287209-05-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-06-7 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-07-8 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-08-9 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-09-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.



RN 287209-10-3 HCAPLUS


CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-  
phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI)

Updated Search

09890219

(CA INDEX NAME)


Absolute stereochemistry.



RN 287209-11-4 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287209-12-5 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-13-6 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-14-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN	287209-15-8	HCAPLUS
CN	L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)	

CCOC(=O)N(C)C(=O)SC(C1=CC=C(C=C1)C(F)=C1)C(=O)N(C)C(=O)SC(C1=CC=C(C=C1)C(O)=CC1C(C)C)C(=O)N(C)C


Absolute stereochemistry.



Absolute stereochemistry.

Updated Search


09890219



RN 287209-18-1 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-19-2 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287209-20-5 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-21-6 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-22-7 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-23-8 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-24-9 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search



09890219


RN 287209-25-0 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-26-1 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-ethyl-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-27-2 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-28-3 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-29-4 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-30-7 HCAPLUS


CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-

Updated Search

09890219


phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 287209-31-8 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287209-32-9 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-33-0 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,α-dimethyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-34-1 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
ethyl-L-valyl-3-(1,1-dimethylethyl)-N,α-dimethyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.


Updated Search

09890219




RN 287209-35-2 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-36-3 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287209-37-4 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-38-5 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-39-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219



RN 287209-40-9 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287209-41-0 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-42-1 HCAPLUS

CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-43-2 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search



09890219


RN 287209-44-3 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-45-4 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-46-5 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-47-6 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-N,3-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-48-7 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-N,3-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-49-8 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-N,3-bis(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287209-50-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-51-2 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-52-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-N-[(methylsulfonyl)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-53-4 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-54-5 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)propyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287209-55-6 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)propyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-58-9 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219




RN 287209-59-0 HCAPLUS  
CN L-Tyrosinamide, L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 287209-60-3 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-  
fluorophenyl)propyl]-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287209-61-4 HCAPLUS  
CN Carbamic acid, [(1S)-1-[[[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-  
(hydroxymethyl)ethyl]amino]carbonyl]-2-methylpropyl]-, phenylmethyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-62-5 HCAPLUS

CN Butanamide, 2-amino-N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-3-methyl-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-63-6 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]amino]carbonyl]-2-methylpropyl]amino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-64-7 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]amino]carbonyl]-2-methylpropyl]methylamino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287209-65-8 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]methylamino]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-66-9 HCAPLUS

CN Butanamide, 2-amino-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,3-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-67-0 HCAPLUS


CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]methylamino]carbonyl]-2-methylpropyl]amino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287209-68-1 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]methylamino]carbonyl]-2-methylpropyl]methylamino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-71-6 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]amino]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287209-72-7 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]amino]carbonyl]-2-methylpropyl]amino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287209-73-8 HCAPLUS

CN Carbamic acid, [(1R)-2-[[[(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]amino]carbonyl]-2-methylpropyl]amino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-75-0 HCAPLUS

CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]amino]carbonyl]-2-methylpropyl]methylamino]-1-[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-76-1 HCAPLUS


CN Carbamic acid, [(1R)-2-[[[(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]amino]carbonyl]-2-methylpropyl]methylamino]-1-

Updated Search

09890219

[(4-fluorophenyl)methyl]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-80-7 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]methylamino]carbonyl]-2-methylpropyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-81-8 HCAPLUS

CN Butanamide, 2-amino-N-[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]-N,3-dimethyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 287209-82-9 HCAPLUS


CN Carbamic acid, [(1S)-2-[[[(1S)-1-[[[(1S)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-(hydroxymethyl)ethyl]methylamino]carbonyl]-2-

Updated Search

09890219

methylpropyl]methylamino]-1-[(4-fluorophenyl)methyl]ethyl]-,  
1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-83-0 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1,1-dimethylethoxy)carbonyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-84-1 HCAPLUS

CN L-Tyrosinamide, L-valyl-N-[(1,1-dimethylethoxy)carbonyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219

RN 287209-85-2 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)propyl]-L-valyl-N-[(1,1-dimethylethoxy)carbonyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287209-86-3 HCAPLUS

CN L-Tyrosinamide, N-[(2S)-2-[[[(1,1-dimethylethoxy)carbonyl]amino]-3-(4-fluorophenyl)propyl]-N-methyl-L-valyl-N-[(1,1-dimethylethoxy)carbonyl]-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-07-5 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-08-6 HCAPLUS

CN	L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-	(9CI)	(CA
	INDEX NAME)		


Absolute stereochemistry.



RN 287210-09-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-10-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Updated Search


09890219

Absolute stereochemistry.



RN 287210-11-1 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-12-2 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-13-3 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-14-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search



09890219


RN 287210-15-5 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-16-6 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-17-7 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-18-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-19-9 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-20-2 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-21-3 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-ethyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-22-4 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-23-5 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-24-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-25-7 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-26-8 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-27-9 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-28-0 HCAPLUS

CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-29-1 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-30-4 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-31-5 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-32-6 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-33-7 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-34-8 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287210-35-9 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-36-0 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N,N $\alpha$ -diethyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-37-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-38-2 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-39-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-propyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287210-40-6 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-41-7 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-42-8 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(1-methylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-43-9 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-N-cyclopropyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-44-0 HCAPLUS  
CN L-Tyrosinamide, N-methyl-L-valyl-N-cyclopropyl-3-(1,1-dimethylethyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-45-1 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-N-cyclopropyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-46-2 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-47-3 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-48-4 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-49-5 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-50-8 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-51-9 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-52-0 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 287210-53-1 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-54-2 HCAPLUS  
CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287210-55-3 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-Nα-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-56-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-Nα-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-57-5 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-58-6 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-59-7 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-60-0 HCAPLUS

CN L-Tyrosinamide, N-ethyl-4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-Nα-ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-61-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-Nα-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-62-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-Nα-ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287210-63-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 287210-64-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-ethyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -ethyl-N-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-65-5 HCAPLUS

Updated Search

09890219

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-66-6 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-67-7 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-(hydroxymethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219

RN 287210-68-8 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(4-morpholinyl)-2-oxoethyl]methylamino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287210-69-9 HCAPLUS

CN Butanamide, N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(4-morpholinyl)-2-oxoethyl]-N,3-dimethyl-2-(methylamino)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-70-2 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-(4-morpholinyl)-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-71-3 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[4-(methylsulfonyl)-1-piperazinyl]-2-oxoethyl]methylamino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-72-4 HCAPLUS

CN Butanamide, N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[4-(methylsulfonyl)-1-piperazinyl]-2-oxoethyl]-N,3-dimethyl-2-(methylamino)-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-73-5 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[4-(methylsulfonyl)-1-piperazinyl]-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-74-6 HCAPLUS


CN 1-Piperazineacetic acid, 4-[N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-methyl-L-tyrosyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287210-75-7 HCAPLUS

CN 1-Piperazineacetic acid, 4-[N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-methyl-L-tyrosyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287210-76-8 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-[(1S)-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-[4-(2-ethoxy-2-oxoethyl)-1-piperazinyl]-2-oxoethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287210-79-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-00-1 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1S)-2-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-oxoethyl]methylamino]carbonyl]propyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-01-2 HCAPLUS

CN Benzenepropanamide, 3-(1,1-dimethylethyl)-4-hydroxy- $\alpha$ -[methyl[(2S)-2-(methylamino)-1-oxobutyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-02-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-(2S)-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219

RN 287211-03-4 HCAPLUS

CN Carbamic acid, [(1R)-1-[[[(1S)-2-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-oxoethyl]methylamino]carbonyl]propyl]methyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-04-5 HCAPLUS

CN Benzenepropanamide, 3-(1,1-dimethylethyl)-4-hydroxy- $\alpha$ -[methyl[(2R)-2-(methylamino)-1-oxobutyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-05-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-(2R)-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219




RN 287211-06-7 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-norvalyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287211-07-8 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287211-08-9 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287211-09-0 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-D-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-10-3 HCAPLUS  
CN L-Tyrosinamide, N-methyl-D-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-11-4 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-D-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-12-5 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-isoleucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search


```

RN      287211-13-6   HCAPLUS
CN      L-Tyrosinamide, N-methyl-L-isoleucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-
        (9CI)  (CA INDEX NAME)

```

CC(C)(C)c1ccc(O)cc1CCS(=O)(=O)C(=O)N[C@@H](C)S[C@H](C)SCC

Absolute stereochemistry.




Absolute stereochemistry.

Updated Search




09890219



RN 287211-16-9 HCAPLUS

CN L-Tyrosinamide, N-methyl-D-isoleucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-17-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-D-isoleucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-18-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 287211-19-2 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-21-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
methyl-L-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-22-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-D-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-23-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-D-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287211-24-9 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-D-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287211-25-0 HCAPLUS  
CN L-Tyrosinamide, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-26-1 HCAPLUS  
CN L-Tyrosinamide, 4,5-didehydro-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219



RN 287211-27-2 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
4,5-didehydro-N-methyl-L-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-28-3 HCAPLUS  
CN L-Tyrosinamide, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-N-  
methylnorvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-29-4 HCAPLUS

CN L-Tyrosinamide, 4,5-didehydro-N-methylnorvalyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-30-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
4,5-didehydro-N-methyl-D-norvalyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN	287211-31-8	HCAPLUS
CN	L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N,4-dimethyl-L-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)	

Chemical structure of compound 10: A 1,3-bis(2-methyl-2-oxo-1,3-dihydro-4-phenylthio-5-phenylthio)propan-2-one derivative. It features a central carbon atom bonded to two phenylthio groups and a 2-methyl-2-oxo-1,3-dihydro-4-phenylthio-5-phenylthio group. The structure is shown with stereochemistry.

Absolute stereochemistry.



Updated Search

09890219

287212-05-9P 287212-06-0P 287212-07-1P  
287212-08-2P 287212-09-3P 287212-10-6P  
287212-11-7P 287212-12-8P 287212-13-9P  
287212-14-0P 287212-15-1P 287212-16-2P  
287212-23-1P 287212-24-2P 287212-25-3P  
287212-46-8P 287212-47-9P 287212-49-1P  
287212-50-4P 287212-52-6P 287212-53-7P  
287212-54-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of peptides or analogs containing substituted phenethylamine  
moiety  
as motilin receptor antagonists and drugs for preventing digestive  
tract movement or high level of blood motilin)

RN 287211-33-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
N,4-dimethyl-L-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



RN 287211-34-1 HCAPLUS


CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N,4-dimethyl-D-leucyl-3-  
(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287211-35-2 HCAPLUS

CN L-Tyrosinamide, N, 4-dimethyl-D-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-36-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
N,4-dimethyl-D-leucyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287211-37-4 HCAPLUS  
CN Carbamic acid, [1-[[[(1S)-2-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-2-oxoethyl]methylamino]carbonyl]-3,3,3-trifluoropropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287211-38-5 HCAPLUS  
CN Benzenepropanamide, 3-(1,1-dimethylethyl)-4-hydroxy- $\alpha$ -[methyl[(2S)-4,4,4-trifluoro-2-(methylamino)-1-oxobutyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-39-6 HCAPLUS  
CN Benzenepropanamide, 3-(1,1-dimethylethyl)-4-hydroxy- $\alpha$ -[methyl[(2R)-4,4,4-trifluoro-2-(methylamino)-1-oxobutyl]amino]-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-40-9 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-(2S)-4,4,4-trifluoro-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-42-1 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-(2R)-4,4,4-trifluoro-2-(methylamino)butanoyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-49-8 HCAPLUS

CN L-Tyrosinamide, 3-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-50-1 HCAPLUS

CN L-Tyrosinamide, 3-cyclohexyl-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219



RN 287211-51-2 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-3-cyclohexyl-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287211-52-3 HCAPLUS  
CN L-Tyrosinamide, 3-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-D-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-53-4 HCAPLUS

CN L-Tyrosinamide, 3-cyclohexyl-N-methyl-D-alanyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-54-5 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-3-  
cyclohexyl-N-methyl-D-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-55-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-56-7 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN	287211-57-8	HCAPLUS
CN	L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)	

Chemical structure of compound 10: A symmetrical molecule featuring two 4-fluorophenyl groups and two 3-hydroxy-4-tert-butylphenyl groups. The central core consists of two amide bonds linked by a sulfur atom. The left amide is N-methyl-2-((4-fluorophenyl)methyl)-4-oxo-4,5-dihydrothiazole-5-sulfonamide, and the right amide is N-methyl-2-((3-hydroxy-4-tert-butylphenyl)methyl)-4-oxo-4,5-dihydrothiazole-5-sulfonamide. The sulfur atom is bonded to the 4-fluorophenyl group and the 3-hydroxy-4-tert-butylphenyl group.

Absolute stereochemistry.




Absolute stereochemistry.

Updated Search




09890219




RN 287211-60-3 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287211-61-4 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-62-5 HCAPLUS

Updated Search

09890219

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-63-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-4-  
fluoro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-66-9 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-D-  
phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-69-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-72-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-4-  
fluoro-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-74-9 HCAPLUS

CN L-Tyrosinamide, 4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-76-1 HCAPLUS

CN L-Tyrosinamide, 4-chloro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-77-2 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-4-chloro-N-methyl-L-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-78-3 HCAPLUS

CN L-Tyrosinamide, 4-chloro-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-79-4 HCAPLUS

CN L-Tyrosinamide, 4-chloro-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-80-7 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-4-  
chloro-N-methyl-D-phenylalanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-81-8 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-tyrosyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-82-9 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-tyrosyl-3-(1,1-dimethylethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-83-0 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-tyrosyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287211-84-1 HCAPLUS


CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-O-(phenylmethyl)-D-tyrosyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 287211-85-2 HCAPLUS

CN L-Tyrosinamide, N-methyl-D-tyrosyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-86-3 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-  
methyl-D-tyrosyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-87-4 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-3-(2-thienyl)-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-88-5 HCAPLUS

CN L-Tyrosinamide, N-methyl-3-(2-thienyl)-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-89-6 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-3-(2-thienyl)-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287211-90-9 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-3-(2-thienyl)-D-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-91-0 HCAPLUS

CN L-Tyrosinamide, N-methyl-3-(2-thienyl)-D-alanyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287211-92-1 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-  
methyl-3-(2-thienyl)-D-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287211-93-2 HCAPLUS

CN L-Tyrosinamide, 3-cyclopropyl-N-methyl-N-[(phenylmethoxy)carbonyl]-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287211-94-3 HCAPLUS

CN L-Tyrosinamide, 3-cyclopropyl-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

RN	287211-95-4	HCAPLUS
CN	L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-3-cyclopropyl-N-methyl-L-alanyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)	
	(CA INDEX NAME)	

CC(C)(C)OC(=O)N(C)C(=O)S[C@H](C1CC1)C(=O)N(C)C(=O)S[C@@H](Cc2ccc(O)c(C(C)(C)C)c2)C(=O)N


Absolute stereochemistry.



Absolute stereochemistry.

Updated Search


09890219



RN 287212-04-8 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N, $\alpha$ -dimethyl-L-phenylalanyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287212-05-9 HCAPLUS

CN L-Tyrosinamide, N, $\alpha$ -dimethyl-N-[(phenylmethoxy)carbonyl]-D-phenylalanyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287212-06-0 HCAPLUS  
CN L-Tyrosinamide, N, $\alpha$ -dimethyl-D-phenylalanyl-3-(1,1-dimethylethyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287212-07-1 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-  
N, $\alpha$ -dimethyl-D-phenylalanyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 287212-08-2 HCAPLUS  
CN L-Tyrosinamide, N,2-dimethyl-N-[(phenylmethoxy)carbonyl]-L-leucyl-3-(1,1-  
dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219




RN 287212-09-3 HCAPLUS  
CN L-Tyrosinamide, N,2-dimethyl-L-leucyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287212-10-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N,2-dimethyl-L-leucyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287212-11-7 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-D-isovalyl-3-(1,1-dimethylethyl)- (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287212-12-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287212-13-9 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287212-14-0 HCAPLUS


CN L-Tyrosinamide, N,3-dimethyl-N-[(phenylmethoxy)carbonyl]-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Updated Search

09890219

dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287212-15-1 HCAPLUS

CN L-Tyrosinamide, N,3-dimethyl-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287212-16-2 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N,3-dimethyl-D-isovalyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287212-23-1 HCAPLUS

Updated Search

09890219

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N,3-dimethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 287212-24-2 HCAPLUS

CN L-Tyrosinamide, N,3-dimethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287212-25-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N,3-dimethyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287212-46-8 HCAPLUS

CN L-Tyrosinamide, 3-(2-fluoro-4-pyridinyl)-N-[(phenylmethoxy)carbonyl]-L-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 287212-47-9 HCAPLUS

CN L-Tyrosinamide, 3-(2-fluoro-4-pyridinyl)-N-[(phenylmethoxy)carbonyl]-D-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219



RN 287212-49-1 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-3-ethoxy-2-[(4-fluorophenyl)methyl]-1,3-dioxopropyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 287212-50-4 HCAPLUS  
CN L-Tyrosinamide, N-[(2R)-3-ethoxy-2-[(4-fluorophenyl)methyl]-1,3-dioxopropyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219



RN 287212-52-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-3-(4-pyridinyl)-L-alanyl-  
N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




RN 287212-53-7 HCAPLUS  
CN L-Tyrosinamide, 4-cyano-N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-  
methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 287212-54-8 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-tryptophyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:210207 HCAPLUS

DOCUMENT NUMBER: 132:251427

TITLE: Preparation of peptide derivatives as motilin receptor antagonists

INVENTOR(S): Matsuoka, Hiroharu; Sato, Tsutomu

PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan

SOURCE: PCT Int. Appl., 101 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

Updated Search



09890219

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017231	A1	20000330	WO 1999-JP5215	19990924
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
TW 509699	B	20021111	TW 1999-88116326	19990922
AU 9957592	A	20000410	AU 1999-57592	19990924
EP 1116726	A1	20010718	EP 1999-944808	19990924
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 3519367	B2	20040412	JP 2000-574139	19990924
US 6586630	B1	20030701	US 2001-787674	20010321
US 20030176643	A1	20030918	US 2003-356558	20030203
US 6720433	B2	20040413		
PRIORITY APPLN. INFO.:			JP 1998-307784	A 19980924
			WO 1999-JP5215	W 19990924
			US 2001-787674	A3 20010321

OTHER SOURCE(S): MARPAT 132:251427

AB H-Phe-Val-substituted Ala-derivs. represented by general formula  
 $R_3CH(CHR_1R_2)-X-NR_4CH(R_5)-Y-NR_6CH(CH_2R_8)R_7$  [R1 = (un)substituted Ph, heterocyclyl, C2-6 linear or branched alkenyl or alkynyl; R2 = H, (un)substituted C1-3 linear or branched alkyl alkyl, NH2, OH; R3 = H, (un)substituted C1-3 linear or branched alkyl, (un)substituted NH2, OH; R4 = H, Me, Et; R5 = (un)substituted C1-6 linear or branched alkyl, C3-7 cycloalkyl, (un)substituted Ph; R6 = H, Me, Et; R7 = H, (un)substituted C1-3 linear or branched alkyl, (un)substituted CONH2; R8 = (un)substituted C3-9 heterocyclyl, (un)substituted Ph], hydrates, or pharmaceutically acceptable salts thereof are prepared. Drugs containing these compds. as the active ingredient for motilin receptor antagonists, inhibiting movement of digestive tracts, or treating high level of motilin in blood are also claimed. These peptides are useful for the treatment of irritable bowel syndrome. Thus, Me-Val-Phe(3-tert-butyl-4-F)-NH2 (preparation given) was condensed with Boc-Phe-OH using BOP and diisopropylethylamine in CH2Cl2 at room temperature for 22 h, followed by the treatment with CF3CO2H, to give H-Phe-N-Me-Val-Phe(3-tert-butyl-4-F)-NH2 (I). I showed IC50 of 3.5 nM for inhibiting the binding of [125I]motilin to viscous membrane preparation from rabbit ileum.

IT 262360-77-0P 262360-78-1P 262360-79-2P  
 262360-85-0P 262360-90-7P 262362-12-9P  
 262362-15-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of peptide derivs. as motilin receptor antagonists and inhibitors of digestive tract motility)

RN 262360-77-0 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-acetyl- (9CI) (CA INDEX

Updated Search

09890219

NAME )


Absolute stereochemistry.



RN 262360-78-1 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-(1-oxopropyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 262360-79-2 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-(2-methyl-1-oxopropyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262360-85-0 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262360-90-7 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-N $\alpha$ -methyl-3-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262362-12-9 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-D-valyl-N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 262362-15-2 HCAPLUS

CN D-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-N $\alpha$ -methyl-3-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


IT 262360-91-8P 262360-94-1P 262360-95-2P  
262360-98-5P 262361-01-3P 262361-02-4P  
262361-03-5P 262361-07-9P 262361-09-1P  
262361-10-4P 262361-57-9P 262361-58-0P  
262361-61-5P 262361-62-6P 262361-63-7P  
262362-03-8P 262362-21-0P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of peptide derivs. as motilin receptor antagonists and  
inhibitors of digestive tract motility)  
RN 262360-91-8 HCAPLUS  
CN L-Tyrosinamide, N-methyl-L-valyl-3-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 262360-94-1 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-acetyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262360-95-2 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-  
valyl-3-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262360-98-5 HCAPLUS

CN L-Tyrosinamide, N-methylvalyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262361-01-3 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]valyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262361-02-4 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methylvalyl-3-(1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262361-03-5 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-D-valyl-3-(1-oxopropyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262361-07-9 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 262361-09-1 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search



CC(C)S[C@@H](NC(=O)O[C@H](C1=CC=C(C=C1)C(=O)O)C(=O)N)C(=O)NCC1=CC=CC=C1


CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

CC(C)C(=O)N[C@@H](Cc1ccc(cc1C(=O)O)C(=O)OCC)S(=O)(=O)C(=O)N[C@@H](Cc2ccccc2)S(=O)(=O)C(=O)N(C)C(C)C

CN L-Tyrosinamide, N-methyl-L-valyl-N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)-  
(9CI) (CA INDEX NAME)

Updated Search


09890219



RN 262361-58-0 HCAPLUS

CN L-Tyrosinamide, N-methyl-D-valyl-N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262361-61-5 HCAPLUS

CN L-Tyrosinamide, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-N-methylvalyl-  
N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262361-62-6 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-D-valyl-N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262361-63-7 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-N $\alpha$ -methyl-3-(2-methyl-1-oxopropyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 262362-03-8 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-N $\alpha$ -methyl-3-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 262362-21-0 HCAPLUS

CN D-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-N $\alpha$ -methyl-3-[1,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search

09890219



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:23:26 ON 03 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 03 NOV 2008

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 728 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:27:38 ON 03 NOV 2008

L4 47 S L3

FILE 'REGISTRY' ENTERED AT 17:27:44 ON 03 NOV 2008

L5 STRUCTURE UPLOADED

L6 4 S L5

L7 700 S L5 FULL

L8 0 S L7 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:33:10 ON 03 NOV 2008

L9 41 S L7

L10 3 S L9 AND MATSUOKA, H?/AU

=> s l9 not l10

L11 38 L9 NOT L10

=> s l11 and sato, t?/au

26088 SATO, T?/AU

L12 2 L11 AND SATO, T?/AU

=> d l12, ibib abs hitstr, 1-2

L12 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:90066 HCAPLUS

DOCUMENT NUMBER: 136:135034

TITLE: Method for producing tripeptide derivative

Updated Search

09890219

INVENTOR(S): Sato, Tsutomu; Shimizu, Hirohito  
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan  
SOURCE: PCT Int. Appl., 50 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008248	A1	20020131	WO 2001-JP6295	20010719
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
JP 2005097119	A	20050414	JP 2000-219977	20000721
PRIORITY APPLN. INFO.:			JP 2000-219977	A 20000721
OTHER SOURCE(S):	CASREACT 136:135034; MARPAT 136:135034			
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB A method for producing L-phenylalanyl-L-valyl-L-3-tert-butyl-L-tyrosinamide compds. represented by the general formula (I; wherein R1 represents a hydrogen atom or a linear or branched aliphatic alkyl group having 1 to 4 carbon atoms; R2 represents a hydrogen atom or Me group; R3 represents a hydrogen atom or Me group; and R4 represents a halogen atom) comprises condensation of 3-tert-butyl-L-tyrosinamide derivs. (II; R1, R2 = same as above) with N-methyl-L-valine derivs. (III; P1 = amino-protecting group), N-deprotection of the resulting L-valyl-3-tert-butyl-L-tyrosinamide derivs. (IV; R1, R2, P1 = same as above), and condensation of the resulting IV (P1 = H; R1, R2 = same as above) with L-phenylalanine derivs. (V; R3, R4 = same as above; P2 = amino-protecting group) followed by N-deprotection. The method can be advantageously used for producing a novel peptide derivative in a com. process. Thus, 20.8 g MeSO<sub>3</sub>H and 20.0 g tert-Bu chloride were successively added to 10.0 g L-tyrosine Me ester hydrochloride under stirring, stirred at 50° for 5 h, treated dropwise with MeOH (20 mL)/H<sub>2</sub>O (20 mL) under ice-cooling then with a solution of 14.2 g KOH in 43 mL H<sub>2</sub>O at <10° to give 77.0% 3-tert-butyl-L-tyrosine Me ester which (8.35 g) was added to a mixture of 24.1 g 62% aqueous ethylamine and 7.52 g ethylamine hydrochloride under ice-cooling and stirred at room temperature for 5 h to give 89.8% 3-tert-butyl-L-tyrosine ethylamide (VI). To a solution of 5.50 g VI and 3.35 g 1-hydroxybenzotriazole monohydrate in 55 mL THF were successively added 4.19 g 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 3.04 mL Et<sub>3</sub>N and stirred at room temperature for 2.5 h to give


Updated Search

09890219

100% N-tert-butoxycarbonyl-N-methyl-L-valyl-3-tert-butyl-L-tyrosine ethylamide which (10.0 g) was dissolved in 100 mL EtOAc, treated with 11.1 mL concentrated H<sub>2</sub>SO<sub>4</sub> under ice-cooling, treated with 100 mL EtOAc, adjusted pH 8 by adding saturated aqueous NaHCO<sub>3</sub>, and stirred 15 min to give 87.9% N-methyl-L-valyl-3-tert-butyl-L-tyrosine ethylamide (VII). To a mixture of 5.50 g VII, 5.20 g N-tert-butoxycarbonyl-N-methyl-4-fluoro-L-phenylalanine, 4.47 g 2-chloro-1-methylpyridinium iodide, and 37 mL tert-Bu Me ether was added 5.09 mL Et<sub>3</sub>N and stirred at room temperature for 4 h to give 86.0% N-tert-butoxycarbonyl-N-methyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-tert-butyl-L-tyrosine ethylamide which (7.50 g) was similarly deprotected as described above using concentrated H<sub>2</sub>SO<sub>4</sub> in EtOAc to give 100% N-methyl-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-tert-butyl-L-tyrosine.


IT 220808-88-8P 287210-08-6P 287210-10-0P  
393561-99-4P 393562-02-2P 393562-03-3P  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation tripeptide derivs. by sequential coupling of N-methyl-L-valine derivs. and L-phenylalanine derivs. to 3-tert-butyl-L-tyrosinamide derivs.)  
RN 220808-88-8 HCAPLUS  
CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N- $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 287210-08-6 HCAPLUS  
CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 287210-10-0 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393561-99-4 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393562-02-2 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search




09890219



RN 393562-03-3 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 287205-81-6P 287206-61-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)

(preparation tripeptide derivs. by sequential coupling of N-methyl-L-valine derivs. and L-phenylalanine derivs. to 3-*tert*-butyl-L-tyrosinamide derivs.)


RN 287205-81-6 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219



RN 287206-61-5 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L12 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 1999:139868 HCAPLUS  
DOCUMENT NUMBER: 130:196958  
TITLE: Preparation of 3-tert-butyl-L-tyrosinamide-containing peptides and related compounds exhibiting a motilin receptor antagonism  
INVENTOR(S): Kotake, Ken-ichiro; Kozono, Toshiro; Sato, Tsutomu; Takanashi, Hisanori  
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan  
SOURCE: PCT Int. Appl., 144 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

Updated Search

09890219



```

-----
WO 9909053          A1      19990225      WO 1998-JP3627          19980814
W:  AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
    DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, KE, KG, KR,
    KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
    PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG,
    US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
    FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
    CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

TW 460478          B      20011021      TW 1998-87113211        19980811
CA 2301687        A1      19990225      CA 1998-2301687        19980814
AU 9886490        A      19990308      AU 1998-86490          19980814
AU 741216         B2      20011129
JP 2000044595     A      20000215      JP 1998-229586         19980814
JP 3583928       B2      20041104
EP 1006122       A1      20000607      EP 1998-937826         19980814
R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
    IE, FI
US 6255285       B1      20010703      US 2000-485620         20000215
PRIORITY APPLN. INFO.:
                                JP 1997-255879         A 19970815
                                JP 1998-186802         A 19980528
                                WO 1998-JP3627          W 19980814

OTHER SOURCE(S):      MARPAT 130:196958
GI

```



AB Phenethylamine derivs. represented by general formula [I; wherein A represents an amino acid or  $\alpha$ -substituted amino acid residue; R1 represents R6CO, (un)substituted C2-7 linear or branched alkyl, C3-8 alkenyl, or C3-8 alkynyl; R2 represents hydrogen, C1-3 linear or branched

Updated Search

alkyl; R3 represents COR7, (un)substituted C1-5 linear or branched alkyl, C2-5 alkenyl, or C2-5 alkynyl; R4 represents H, C1-6 linear or branched alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R5 represents hydroxy or C1-4 n-alkoxy; R6 represents (un)substituted C1-6 linear or branched alkyl, C2-7 alkenyl, or C2-7 alkynyl, optionally benzene- or heterocyclic ring-condensed C3-7 cycloalkyl, (un)substituted C6-12 aromatic ring, (un)substituted C3-12 (un)saturated heterocyclic ring, (un)substituted NH2, (un)substituted linear or branched C1-5 alkoxy, C2-6 alkenyloxy, C2-6 alkynyloxy, etc.; and R7 represents H, (un)substituted C1-5 linear or branched alkyl, C3-7 cycloalkyl, (un)substituted NH2, OH, linear or branched alkyl C1-6 alkoxy, or C3-7 cycloalkyloxy] are prepared Also claimed are a motilin receptor antagonist, an inhibitor of digestive tract motility, and a remedy for high blood motilin. They are also useful for the treatment of irritable bowel syndrome. Thus, Na-methyl-N-[2-(3-tert-butyl-4-hydroxyphenyl)-1-methylethyl]-L-valinamide was condensed with Boc-Phe-OH using HOBT and DIC in DMF at room temperature for 2.5 days followed by deprotection with CF3CO2H in CH2Cl2 to

give

the title compound (II). II in vitro showed IC50 of 1.9 nM for inhibiting the binding of [125I]motilin motilin receptor preparation from rabbit ileum mucous membrane.

IT 220806-45-1P 220806-47-3P 220806-49-5P  
 220806-51-9P 220806-59-7P 220806-61-1P  
 220806-63-3P 220806-69-9P 220806-71-3P  
 220806-75-7P 220806-77-9P 220806-79-1P  
 220806-81-5P 220806-83-7P 220806-85-9P  
 220806-87-1P 220806-89-3P 220806-91-7P  
 220806-93-9P 220806-95-1P 220806-97-3P  
 220806-99-5P 220807-01-2P 220807-03-4P  
 220807-05-6P 220807-07-8P 220807-09-0P  
 220807-11-4P 220807-19-2P 220808-01-5P  
 220808-02-6P 220808-03-7P 220808-04-8P  
 220808-05-9P 220808-06-0P 220808-07-1P  
 220808-08-2P 220808-09-3P 220808-10-6P  
 220808-16-2P 220808-17-3P 220808-18-4P  
 220808-19-5P 220808-20-8P 220808-26-4P  
 220808-27-5P 220808-28-6P 220808-29-7P  
 220808-30-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-tert-butyl-L-tyrosinamide-containing peptide compds. as motilin receptor antagonists, inhibitors of digestive tract motility, and remedy for high blood motilin)

RN 220806-45-1 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-phenylalanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 220806-44-0

CMF C31 H38 N4 O4

Absolute stereochemistry.


09890219



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-47-3 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-46-2

CMF C27 H38 N4 O4

Absolute stereochemistry.




CM 2

Updated Search

09890219

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-49-5 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-alanyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-48-4  
CMF C25 H34 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-51-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-leucyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

Updated Search

09890219


CRN 220806-50-8  
CMF C28 H40 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-59-7 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-tyrosyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

CRN 220806-58-6  
CMF C31 H38 N4 O5

Absolute stereochemistry.

Updated Search


09890219



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-61-1 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-( $\alpha$ S)- $\alpha$ -aminobenzenebutanoyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-60-0

CMF C32 H40 N4 O4

Absolute stereochemistry.




CM 2

Updated Search



09890219

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-63-3 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-3-(2-thienyl)-L-alanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-62-2  
CMF C29 H36 N4 O4 S

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-69-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-2-methylalanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Updated Search


09890219

CM 1

CRN 220806-68-8

CMF C26 H36 N4 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-71-3 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-isoleucyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-70-2

CMF C28 H40 N4 O4

Absolute stereochemistry.

Updated Search


09890219



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-75-7 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-3-cyclohexyl-L-alanyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-74-6

CMF C31 H44 N4 O4

Absolute stereochemistry.




CM 2

Updated Search

09890219

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-77-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-3-methyl-L-valyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-76-8  
CMF C28 H40 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-79-1 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L- $\alpha$ -aspartyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Updated Search


09890219

CM 1

CRN 220806-78-0

CMF C26 H34 N4 O6


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-81-5 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L- $\alpha$ -glutamyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-80-4

CMF C27 H36 N4 O6

Absolute stereochemistry.

Updated Search


09890219



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-83-7 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-5-carboxy-L-norvalyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-82-6

CMF C28 H38 N4 O6

Absolute stereochemistry.




CM 2

Updated Search

09890219

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-85-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-asparaginy1-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-84-8  
CMF C26 H35 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-87-1 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-glutaminy1-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

Updated Search

09890219


CRN 220806-86-0  
CMF C27 H37 N5 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-89-3 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-6-oxo-L-lysyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-88-2  
CMF C28 H39 N5 O5

Absolute stereochemistry.




Updated Search



09890219

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-91-7 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-(2S)-2,4-diaminobutanoyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-90-6  
CMF C26 H37 N5 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220806-93-9 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-ornithyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

Updated Search


09890219

CM 1

CRN 220806-92-8

CMF C27 H39 N5 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-95-1 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-lysyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-94-0

CMF C28 H41 N5 O4

Absolute stereochemistry.

Updated Search


09890219



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220806-97-3 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-seryl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220806-96-2

CMF C25 H34 N4 O5

Absolute stereochemistry.




CM 2

Updated Search

09890219

CRN 76-05-1  
CMF C2 H F3 O2




RN 220806-99-5 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-homoseryl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220806-98-4  
CMF C26 H36 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220807-01-2 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-threonyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)


CM 1

Updated Search

09890219


CRN 220807-00-1  
CMF C26 H36 N4 O5

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220807-03-4 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-(2S)-2-aminobutanoyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-02-3  
CMF C26 H36 N4 O4

Absolute stereochemistry.




Updated Search

09890219

CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 220807-05-6 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-norvalyl-3-(1,1-dimethylethyl)-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220807-04-5  
CMF C27 H38 N4 O4

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 220807-07-8 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-methionyl-3-(1,1-dimethylethyl)-,

Updated Search

09890219


mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-06-7

CMF C27 H38 N4 O4 S


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220807-09-0 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-L-histidyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 220807-08-9

CMF C28 H36 N6 O4

Absolute stereochemistry.

Updated Search


09890219



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220807-11-4 HCAPLUS


CN L-Tyrosinamide, L-phenylalanyl-L-tryptophyl-3-(1,1-dimethylethyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220807-10-3

CMF C33 H39 N5 O4

Absolute stereochemistry.



Updated Search




09890219

CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 220807-19-2 HCAPLUS

CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-01-5 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-02-6 HCAPLUS


CN L-Tyrosinamide, 4,5-didehydro-5-methyl-L-norleucyl-N-methyl-L-valyl-3-(1,1-

Updated Search

09890219

dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-03-7 HCAPLUS

CN L-Tyrosinamide, (2S)-2-amino-6-heptynoyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-04-8 HCAPLUS

CN L-Tyrosinamide, 4,4,5,5-tetradecahydro-L-norleucyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 220808-05-9 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(3S)-1-oxo-3-phenylbutyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-06-0 HCAPLUS

CN L-Tyrosinamide, N-methyl-N-[(3R)-1-oxo-3-phenylbutyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-07-1 HCAPLUS

CN L-Tyrosinamide, 3-phenyl- $\beta$ -alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 220808-08-2 HCAPLUS

CN L-Tyrosinamide, N-(1,2-dioxo-3-phenylpropyl)-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-09-3 HCAPLUS

CN L-Tyrosinamide, N-phenylglycyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 220808-10-6 HCAPLUS  
CN L-Tyrosinamide, N-methyl-N-phenylglycyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-16-2 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-17-3 HCAPLUS  
CN L-Valinamide, L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 220808-18-4 HCAPLUS  
CN L-Tyrosinamide, L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-  
N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-19-5 HCAPLUS  
CN L-Valinamide, N-methyl-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-20-8 HCAPLUS  
CN L-Valinamide, L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,N2-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 220808-26-4 HCAPLUS  
CN L-Tyrosinamide, N-(3-phenylbutyl)-L-valyl-3-(1,1-dimethylethyl)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 220808-27-5 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-2-amino-3-phenylpropyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-28-6 HCAPLUS  
CN Butanamide, N-[(1S)-2-amino-1-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]ethyl]-2-[[ (2S)-2-amino-3-phenylpropyl]amino]-3-methyl-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

```
RN 220808-29-7 HCAPLUS
CN L-Tyrosinamide, (2R)-2-amino-6-heptynoyl-N-methyl-L-valyl-3-(1,1-
dimethylethyl)- (9CI) (CA INDEX NAME)
```

CC(C)(C)c1ccc(cc1C[C@H](NC(=O)NC(=O)N)CC(=O)NCC(C)C)C(=O)NCC(C)C

RN	220808-30-0	HCAPLUS
CN	L-Tyrosinamide, 4,4,5,5-tetradehydro-D-norleucyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)	

```


IT 220808-99-1 220809-00-7
RL: RCT (Reactant); RACT (Reactant or reagent)
    (preparation of 3-tert-butyl-L-tyrosinamide-containing peptide compds. as
    motilin receptor antagonists, inhibitors of digestive tract motility,
    and remedy for high blood motilin)
RN 220808-99-1 HCAPLUS
CN L-Tyrosinamide, L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

```

Updated Search




09890219



RN 220809-00-7 HCAPLUS  
CN 10-Oxa-2,5,8-triazadodecanoic acid,  
4-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-11,11-dimethyl-7-(1-  
methylethyl)-6,9-dioxo-, phenylmethyl ester, (4S,7S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 220808-36-6P 220808-37-7P 220808-43-5P  
220808-44-6P 220808-46-8P 220808-63-9P  
220808-65-1P 220808-67-3P 220808-70-8P  
220808-72-0P 220808-73-1P 220808-74-2P  
220808-75-3P 220808-80-0P 220808-83-3P  
220808-84-4P 220808-85-5P 220808-86-6P  
220808-87-7P 220808-88-8P 220808-89-9P  
220808-90-2P 220808-94-6P 220808-95-7P  
220808-96-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(preparation of 3-tert-butyl-L-tyrosinamide-containing peptide compds. as  
motilin receptor antagonists, inhibitors of digestive tract motility,  
and remedy for high blood motilin)

RN 220808-36-6 HCAPLUS  
CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-  
valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 220808-37-7 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-43-5 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-44-6 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search

09890219

Absolute stereochemistry.



RN 220808-46-8 HCAPLUS


CN L-Tyrosinamide, L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-,  
mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 220808-45-7

CMF C19 H31 N3 O3


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 220808-63-9 HCAPLUS


CN L-Tyrosinamide, 4,5-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-5-methyl-L-

Updated Search

09890219

norleucyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-65-1 HCAPLUS

CN L-Tyrosinamide, 2-[[ (1,1-dimethylethoxy)carbonyl]amino]-6-heptynoyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-67-3 HCAPLUS

CN L-Tyrosinamide, 4,4,5,5-tetradehydro-N-[(1,1-dimethylethoxy)carbonyl]norleucyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 220808-70-8 HCAPLUS

CN L-Tyrosinamide, (2Z)-2,3-didehydro-N-[(1,1-dimethylethoxy)carbonyl]-3-phenyl-β-alanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 220808-72-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-N-phenylglycyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Updated Search

09890219


RN 220808-73-1 HCAPLUS  
CN L-Tyrosinamide, N-phenyl-N-[(phenylmethoxy)carbonyl]glycyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-74-2 HCAPLUS  
CN L-Tyrosinamide, N-[(2S)-3-phenyl-2-[[ (phenylmethoxy)carbonyl]amino]propyl]-L-valyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-75-3 HCAPLUS  
CN 10-Oxa-2,5,8-triazadodecanoic acid, 6-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-11,11-dimethyl-3-(1-methylethyl)-4,9-dioxo-, phenylmethyl ester, (3S,6S)- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219




RN 220808-80-0 HCAPLUS  
CN 2,5,8,11-Tetraazadodecanedioic acid,  
9-[[3-(1,1-dimethylethyl)-4-hydroxyphenyl]methyl]-6-(1-methylethyl)-7-oxo-  
3-(phenylmethyl)-, 1,12-bis(phenylmethyl) ester, (3S,6S,9S)- (CA INDEX  
NAME)

Absolute stereochemistry.



RN 220808-83-3 HCAPLUS  
CN Butanamide, N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-  
methylethyl]-3-methyl-2-(methylamino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-84-4 HCAPLUS  
CN Carbamic acid, [(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-  
methylethyl]amino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester  
(9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 220808-85-5 HCAPLUS

CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-86-6 HCAPLUS

CN L-Tyrosine, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 220808-87-7 HCAPLUS


CN L-Tyrosinamide, N-methyl-N-[(phenylmethoxy)carbonyl]-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Updated Search



09890219


Absolute stereochemistry.



RN 220808-88-8 HCAPLUS

CN L-Tyrosinamide, N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl-  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-89-9 HCAPLUS

CN L-Tyrosinamide, N-[(phenylmethoxy)carbonyl]-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N $\alpha$ -methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 220808-90-2 HCAPLUS

CN L-Valinamide, N-(1,1-dimethylethyl)-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N2-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 220808-94-6 HCAPLUS

CN Butanamide, N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,3-dimethyl-2-(methylamino)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 220808-95-7 HCAPLUS

CN Carbamic acid, [(1S)-1-[[[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]methylamino]carbonyl]-2-methylpropyl]methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Updated Search


09890219

Absolute stereochemistry.



RN 220808-96-8 HCAPLUS  
CN L-Valinamide, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-N-[(1R)-2-[3-(1,1-dimethylethyl)-4-hydroxyphenyl]-1-methylethyl]-N,N2-dimethyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> file hcaplus  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
48.77	414.83

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-4.00	-4.00

CA SUBSCRIBER PRICE

FILE 'HCAPLUS' ENTERED AT 17:37:53 ON 03 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December

Updated Search

09890219

26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Nov 2008 VOL 149 ISS 19  
FILE LAST UPDATED: 2 Nov 2008 (20081102/ED)

HCAPlus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 17:23:26 ON 03 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 03 NOV 2008

L1 STRUCTURE UPLOADED  
L2 5 S L1  
L3 728 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:27:38 ON 03 NOV 2008

L4 47 S L3

FILE 'REGISTRY' ENTERED AT 17:27:44 ON 03 NOV 2008

L5 STRUCTURE UPLOADED  
L6 4 S L5  
L7 700 S L5 FULL  
L8 0 S L7 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:33:10 ON 03 NOV 2008

L9 41 S L7  
L10 3 S L9 AND MATSUOKA, H?/AU  
L11 38 S L9 NOT L10  
L12 2 S L11 AND SATO, T?/AU

FILE 'HCAPLUS' ENTERED AT 17:37:53 ON 03 NOV 2008

=> s l11 not l12

L13 36 L11 NOT L12

=> s l13 and takahashi, t?/au

21959 TAKAHASHI, T?/AU

L14 0 L13 AND TAKAHASHI, T?/AU

=> s l13 and kim, d?/au

31142 KIM, D?/AU

L15 1 L13 AND KIM, D?/AU


=> d l15, ibib abs hitstr, 1

Updated Search

09890219

L15 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:637704 HCAPLUS  
DOCUMENT NUMBER: 137:185838  
TITLE: Process for preparation of peptide derivatives  
INVENTOR(S): Kim, Dong Ick; Jeon, Gee Ho; Kim, Sung Jin  
PATENT ASSIGNEE(S): Chugai Seiyaku Kabushiki Kaisha, Japan  
SOURCE: PCT Int. Appl., 40 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064623	A1	20020822	WO 2002-JP1139	20020212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002230216	A1	20020828	AU 2002-230216	20020212
PRIORITY APPLN. INFO.:			KR 2001-6673	A 20010212
			WO 2002-JP1139	W 20020212
OTHER SOURCE(S):	CASREACT 137:185838; MARPAT 137:185838			
GI				



AB The title compds. I [R<sup>1</sup> is hydrogen or linear or branched C1-4 alkyl; R<sup>2</sup> is hydrogen or linear or branched C1-4 alkyl; and R<sup>3</sup> is halogeno] are prepared in a multistep process. I are motilin receptor antagonists and are useful as drugs for gastric or intestinal diseases (no data). Thus, amidation of N-(tert-butoxycarbonyl)-L-(4-fluorophenyl)alanine with L-valine Me ester hydrochloride, followed by methylation with iodomethane, saponification, reaction with 3-tert-butyl-L-tyrosine Et amide, and deprotection,

Updated Search

09890219

gave N-methyl-L-4-fluorophenylalanyl-N-methyl-L-valine-3-tert-butyl-L-tyrosine Et amide.

IT 287206-61-5P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(process for preparation of peptide derivs.)

RN 287206-61-5 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



IT 287210-10-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(process for preparation of peptide derivs.)

RN 287210-10-0 HCAPLUS

CN L-Tyrosinamide, N-[(1,1-dimethylethoxy)carbonyl]-4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search

09890219

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 17:23:26 ON 03 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 03 NOV 2008

L1 STRUCTURE UPLOADED

L2 5 S L1

L3 728 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:27:38 ON 03 NOV 2008

L4 47 S L3

FILE 'REGISTRY' ENTERED AT 17:27:44 ON 03 NOV 2008

L5 STRUCTURE UPLOADED

L6 4 S L5

L7 700 S L5 FULL

L8 0 S L7 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:33:10 ON 03 NOV 2008

L9 41 S L7

L10 3 S L9 AND MATSUOKA, H?/AU

L11 38 S L9 NOT L10

L12 2 S L11 AND SATO, T?/AU

FILE 'HCAPLUS' ENTERED AT 17:37:53 ON 03 NOV 2008

L13 36 S L11 NOT L12

L14 0 S L13 AND TAKAHASHI, T?/AU

L15 1 S L13 AND KIM, D?/AU

=> s l13 not l15

L16 35 L13 NOT L15

=> s l16 and jung, k?/au

3315 JUNG, K?/AU

L17 0 L16 AND JUNG, K?/AU

=> s l16 and park, c?/au

12758 PARK, C?/AU

L18 0 L16 AND PARK, C?/AU

=> d l16, ibib abs hitstr, 1-35

L16 ANSWER 1 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:1179883 HCAPLUS

TITLE: Process for synthesizing cyclic peptide compound

INVENTOR(S): Suga, Hiroaki; Murakami, Hiroshi; Goto, Yuki;  
Yamagishi, Yusuke; Ashigai, Hiroshi; Sako, Yusuke

PATENT ASSIGNEE(S): The University of Tokyo, Japan

SOURCE: PCT Int. Appl., 82pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

Updated Search

09890219

FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008117833	A1	20081002	WO 2008-JP55771	20080326
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			JP 2007-80141	A 20070326
GI				

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB It is intended to provide a novel process for synthesizing a cyclic peptide compound and a novel cyclic peptide compound. Namely, a process for synthesizing a cyclic peptide compound comprises: (1) the step of synthesizing a non-cyclic peptide compound, which has a pair of functional groups capable of undergoing a bond-forming reaction, i.e., one functional group 1 and another functional group 2, in its mol. via translational synthesis; and (2) the step of cyclizing the above-described non cyclic peptide compound by the bond-forming reaction between the functional groups 1 and 2 as described above. This process uses a cell-free translation system comprising a ribozyme capable of catalyzing aminoacylation reaction of tRNA with amino acids and peptide coupling to synthesize a noncyclic peptide which is then cyclized to give a desired cyclic peptide. A novel cyclic peptide compound (I) was prepared by adding a DNA template, asparagine-specific tRNA containing GAG anticodon aminoacylated by R-Asp-Tyr-Lys-Asp-Asp-Asp-Lys-OH (R = L-3-phenyllactic acid residue) (R-flag), asparagine-specific tRNA containing CAU anticodon aminoacylated by N-chloroacetyl-L-tryptophan, L-phenylalanine, L-glutamic acid, glycine, L-tyrosine, L-aspartic acid, L-asparagine, L-threonine, L-proline, L-cysteine, L-lysine, and the ribozyme, i.e. GGAUCGAAAGAUUCCGCGCCCCGAAAGGGGAUUAGCGUUAGGU or GGAUCGAAAGAUUCCGCAUCCCCGAAAGGGUACAUGGCGUUAGGU, in a reaction system to give a cyclic peptide containing R-flag peptide which was purified by affinity chromatog. using FLAG antibody and heated in a Bicine buffer at 95° for 30 min to give the desired cyclic peptide I.

IT 1065570-13-9P  
RL: BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation)  
(process for preparation of cyclic peptide compound by cell-free translation system using ribozyme as aminoacylation catalyst to prepare noncyclic peptide)

Updated Search




09890219


RN 1065570-13-9 HCAPLUS  
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



Updated Search



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 2 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:447806 HCAPLUS

DOCUMENT NUMBER: 148:532643

TITLE: Zinc(II)-Coordinated Oligotyrosine: A New Class of Cell Penetrating Peptide

AUTHOR(S): Johnson, James R.; Jiang, Hua; Smith, Bradley D.

CORPORATE SOURCE: Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN, 46556, USA

SOURCE: Bioconjugate Chemistry (2008), 19(5), 1033-1039

CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A new series of cell penetrating peptides (CPPs) are described. The peptides are oligomers of Tyr-ZnDPA, a tyrosine derivative with an appended 2,2'-dipicolylamine unit that forms a very stable coordination complex with a zinc (II) cation. This in turn allows reversible association with a chelating oxyanion such as a carboxylate or phosphate derivative. The peptide oligomers (Tyr-ZnDPA)<sub>n</sub> where n = 1, 2, 4, 8, are highly water soluble, but upon association with fatty acids or phospholipids they partition into an organic

octanol phase. Furthermore, a fluorescent, fluorescein-labeled version of the octamer, (Tyr-ZnDPA)<sub>8</sub>-Fl, can enter living mammalian cells via endocytosis and a biotin derivative can deliver fluorescein-labeled streptavidin. Fluorescence microscopy and flow cytometry expts. show that cell uptake is diminished by conditions that inhibit endocytosis. Addnl., uptake of (Tyr-ZnDPA)<sub>8</sub>-Fl is greater than fluorescein labeled octaarginine (Arg<sub>8</sub>-Fl) in all cell lines tested (CHO, COS-7, HeLa). Another difference with Arg<sub>8</sub>-Fl is that cell uptake of (Tyr-ZnDPA)<sub>8</sub>-Fl does not require the presence of heparan sulfate proteoglycans on the cell surface. This difference may eventually be of practical value because drug delivery systems that employ alternative endocytic mechanisms may be optimal for different cell lines or they may deliver selectively to different organelles within a cell.

IT 1024613-48-6P 1024613-49-7P

RL: BUU (Biological use, unclassified); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(zinc(II)-coordinated oligotyrosine as new class of cell penetrating peptide)

RN 1024613-48-6 HCAPLUS


CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[5-[(3aS,4S,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-tyrosyl-3-

09890219

[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




09890219


PAGE 1-B



PAGE 2-A



PAGE 2-B



RN 1024613-49-7 HCAPLUS

CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[5-[(3aS,4S,6aR)-


Updated Search

09890219




hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-tyrosyl-3-  
[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-  
pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-  
pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-  
pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-  
pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-  
pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)



Absolute stereochemistry.


PAGE 1-A



Updated Search








PAGE 4-A


IT 1024613-31-7  
 RL: PRP (Properties); RCT (Reactant); RACT (Reactant or reagent)  
 (zinc(II)-coordinated oligotyrosine as new class of cell penetrating  
 peptide)  
 RN 1024613-31-7 HCAPLUS  
 CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[(1,1-  
 dimethylethoxy)carbonyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-  
 , methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








```

IT      1024613-32-8 1024613-33-9 1024613-36-2
        1024613-37-3 1024613-38-4 1024613-39-5
        1024613-40-8
        RL: RCT (Reactant); RACT (Reactant or reagent)
            (zinc(II)-coordinated oligotyrosine as new class of cell penetrating
            peptide)
RN      1024613-32-8  HCAPLUS
CN      L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[(1,1-
        dimethylethoxy)carbonyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-
        L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-
        pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)




```

Absolute stereochemistry.

PAGE 1-A



Updated Search




RN 1024613-33-9 HCAPLUS  
 CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)


09890219

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




Updated Search



09890219




PAGE 2-A



PAGE 2-B



PAGE 3-A



RN 1024613-36-2 HCAPLUS


Updated Search

09890219


CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 1024613-37-3 HCAPLUS


CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.


Updated Search

09890219

PAGE 1-A





PAGE 1-B




RN 1024613-38-4 HCAPLUS  
CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[(1,1-dimethylethoxy)carbonyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]- (CA INDEX NAME)

Absolute stereochemistry.


Updated Search









RN 1024613-39-5 HCAPLUS  
 CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.








RN 1024613-40-8 HCAPLUS  
 CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)


09890219

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B




Updated Search



09890219




PAGE 2-A



PAGE 2-B



PAGE 3-A



IT 1024613-42-0P 1024613-43-1P 1024613-44-2P

Updated Search

09890219

1024613-46-4P 1024613-47-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(zinc(II)-coordinated oligotyrosine as new class of cell penetrating peptide)

RN 1024613-42-0 HCAPLUS


CN L-Tyrosine, N-(6-amino-1-oxohexyl)-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 1024613-43-1 HCAPLUS

CN L-Tyrosine, N-(6-amino-1-oxohexyl)-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)



Absolute stereochemistry.

Updated Search



09890219



PAGE 2-A




RN	1024613-44-2	HCAPLUS
CN	L-Tyrosine, N-(6-amino-1-oxohexyl)-3-[[bis(2-pyridinylmethyl)amino]methyl]- L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2- pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2- pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2- pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2- pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2- pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2- pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)	

Absolute stereochemistry.


Updated Search




09890219






PAGE 2-A



PAGE 2-B









RN 1024613-46-4 HCAPLUS

CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]-1-oxohexyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.







RN 1024613-47-5 HCAPLUS

CN L-Tyrosine, 3-[[bis(2-pyridinylmethyl)amino]methyl]-N-[6-[[[(3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-[9H]xanthen]-5-yl)amino]thioxomethyl]amino]-1-oxohexyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-L-tyrosyl-3-[[bis(2-pyridinylmethyl)amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.

Updated Search





REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:172923 HCAPLUS

DOCUMENT NUMBER: 148:299702

TITLE: Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits

AUTHOR(S): Sudo, Hirokazu; Yoshida, Shoshin; Ozaki, Ken-ichi; Muramatsu, Hiroyasu; Onoma, Mitsu; Yogo, Kenji; Kamei, Kenshi; Cynshi, Osamu; Kuromaru, Osamu; Peeters, Theo L.; Takanashi, Hisanori

CORPORATE SOURCE: Fuji-Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Shizuoka, 412-8513, Japan

SOURCE: European Journal of Pharmacology (2008), 581(3), 296-305

CODEN: EJPHAZ; ISSN: 0014-2999

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal


LANGUAGE: English

AB The pharmacol. properties of MA-2029, a novel motilin receptor antagonist, were investigated. In vitro, MA-2029 (1 to 30 nM) competitively inhibited motilin-induced contractions in isolated rabbit duodenal longitudinal muscle strips, with a  $pA_2$  value of  $9.17 \pm 0.01$  ( $n = 5$ ). However, contractile responses to acetylcholine and substance P were unaffected even at 1  $\mu M$  of MA-2029. MA-2029 concentration-dependently inhibited the binding of [ $^{125}I$ ]motilin to motilin receptors in a homogenate of rabbit colon smooth muscle tissue and membranes of HEK 293 cells expressing human motilin receptors. The  $pK_i$  of MA-2029 was  $8.58 \pm 0.04$  in the rabbit colon homogenate ( $n = 4$ ) and 8.39 in the HEK 293 cells (mean of duplicate expts.). In vivo, orally-administered MA-2029 (3 to 30 mg/kg) dose-dependently inhibited colonic contractions induced by motilin (3  $\mu g/kg$ , i.v.) in conscious rabbits. Inhibition was caused by all doses at 30 min after administration and by 10 mg/kg or more at 4 h after administration. The plasma concentration of MA-2029 correlated with its inhibitory effect. Furthermore, the oral administration of MA-2029 (0.3 to 3 mg/kg) also inhibited abdominal muscle contractions (an index of the visceral pain) induced by i.v. infusion of motilin (3  $\mu g/kg/h$ ) during colorectal distension in conscious rabbits. These results indicate that MA-2029 is an orally active, selective and competitive motilin receptor antagonist. It is suggested that this compound may be useful for gastrointestinal disorders associated with disturbed gastrointestinal

09890219

motility such as irritable bowel syndrome.  
IT 287206-61-5, MA-2029  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(oral motilin receptor antagonist MA-2029 inhibits intestinal  
contractions and visceral pain)  
RN 287206-61-5 HCAPLUS  
CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-  
dimethylethyl)-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 4 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:106928 HCAPLUS

DOCUMENT NUMBER: 148:221501

TITLE: Characterization of MA-2029 hydrochloride solvates,  
desolvates, and a hydrate

AUTHOR(S): Takata, Noriyuki; Hayashi, Yoshiki; Machida, Minoru;  
Terada, Katsuhide

CORPORATE SOURCE: Department of Pharmaceutics, Faculty of Pharmaceutical  
Science, Toho University, 2-2-1 Miyama, Funabashi,  
Chiba, 274-8501, Japan

SOURCE: Asian Journal of Pharmaceutical Sciences (Hong Kong,  
China) (2006), 1(3-4), 146-158  
CODEN: AJPSGU; ISSN: 1818-0876

PUBLISHER: Hong Kong Asiamed Publish House

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Purpose: To characterize the desolvation and hydration behavior of MA-2029  
hydrochloride solvates, desolvates, and a hydrate. Methods: MA-2029  
hydrochloride solvates, desolvates, and a hydrate were characterized by  
powder X-ray diffraction, crystal structure determination, moisture sorption  
anal., and differential scanning calorimetry. Results: The solvates  
crystallized from acetonitrile/water and Et acetate saturated with water were  
identified as acetonitrile solvated hemihydrate and Et acetate solvated  
hemihydrate, resp. Both solvates possessed essentially similar lattice  
parameters and similar MA-2029 conformations despite having different  
solvents, and had tunnel structures filled with the solvent mols., which

Updated Search

were maintained after desolvation. After desolvation, the vacant tunnels caused nonstoichiometric and extreme hygroscopicity at low relative humidity and they were maintained upon hydration. On heating the hydrate, disruption of the crystal lattice after dehydration was observed prior to melting and this was reflected in the enthalpies of fusion of the dehydrate that fell as the heating rate was reduced. Conclusions: MA-2029 hydrochloride solvates were classified as clathrates which possess tunnel structures. The tunnel structures caused their several specific physicochem. features in the desolvation and hydration processes: isomorphism between both solvates despite having different solvents, hydration into vacant tunnels created after desolvation, and disruption of crystal lattices of the dehydrate prior to melting during the heating process.

IT 922190-03-2, MA 2029 hydrochloride


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(MA-2029 hydrochloride solvates like acetonitrile solvated hemihydrate and Et acetate solvated hemihydrate showed similar lattice parameters and had tunnel structures filled with solvent, which were maintained after desolvation)

RN 922190-03-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1298385 HCAPLUS

DOCUMENT NUMBER: 146:177451

TITLE: Delineation of the motilin domain involved in desensitization and internalization of the motilin receptor by using full and partial antagonists

AUTHOR(S): Mitselos, Anna; Depoortere, Inge; Peeters, Theo L.

CORPORATE SOURCE: Centre for Gastroenterological Research, Catholic

09890219

SOURCE: University of Leuven, Louvain, B-3000, Belg.  
Biochemical Pharmacology (2007), 73(1), 115-124  
CODEN: BCPA6; ISSN: 0006-2952  
PUBLISHER: Elsevier B.V.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Studies with fragments of the gastrointestinal peptide, motilin, indicate that the C-terminal region of this peptide plays an important role in the desensitization of the motilin receptor (MTLR). To verify this hypothesis, we studied the desensitization, phosphorylation and internalization induced by motilin analogs of different chain length with agonistic and antagonistic properties in CHO-MTLR cells. We studied motilin [1-22], the [1-14] fragment, the analogs Phe3[1-22] and Phe3[1-14], and two putative antagonists, GM-109 and MA-2029 (modified 1-4 and 1-3 fragments). Activation and desensitization (2 h preincubation with the motilin analogs 10  $\mu$ M) were studied in CHO-MTLR cells by an aequorin based luminescence assay. Phosphorylation was studied by immunopptn. and internalization was visualized in CHO-MTLR cells containing an enhanced green fluorescent protein (CHO-MTLR-EGFP). Results showed that Motilin [1-22] and [1-14] were more potent than Phe3[1-22] and Phe3[1-14] (pEC50: 9.77, 8.78, 7.36 and 6.65, resp.) to induce Ca<sup>2+</sup> release. GM-109 and MA-2029 were without agonist activity. Motilin[1-22] and Phe3[1-22] decreased the second response to motilin from 78 $\pm$ 2% to 11 $\pm$ 3% and 34 $\pm$ 3% (P < 0.001), resp., whereas [1-14], Phe3[1-14], GM-109 and MA-2029 had no desensitizing effect (68 $\pm$ 5%, 78 $\pm$ 3%, 78 $\pm$ 6% and 78 $\pm$ 5%, resp., P > 0.05). The rank order of MTLR-phosphorylation was: [1-22] > [1-14] > Phe3[1-22] = Phe3[1-14] > GM-109 = MA-2029. Only motilin [1-22] and [1-14] induced receptor MTLR-EGFP internalization as shown by a decrease in membrane fluorescence: 20 $\pm$ 3% and 7 $\pm$ 3%, resp. Thus, the C-terminus of motilin enhances desensitization, phosphorylation and internalization of the MTLR while modifications of the N-terminus can favor a conformation of the receptor that is less susceptible to phosphorylation and internalization.

IT 922190-03-2, MA 2029

RL: BSU (Biological study, unclassified); PKT (Pharmacokinetics); PRP (Properties); BIOL (Biological study)


(motilin receptor antagonist; delineation of motilin domain involved in desensitization, phosphorylation and internalization of motilin receptor by using full and partial antagonists)

RN 922190-03-2 HCAPLUS

CN L-Tyrosinamide, 4-fluoro-N-methyl-L-phenylalanyl-N-methyl-L-valyl-3-(1,1-dimethylethyl)-N-ethyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.

09890219



● HCl

REFERENCE COUNT: 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:600044 HCAPLUS

DOCUMENT NUMBER: 145:201969

TITLE: Development of Peptidic Dopamine Transporter Inhibitors via Aromatic Modification-Mediated Conformational Restriction

AUTHOR(S): Ding, Jinguo; Shi, Jiahao; Cui, Dafu; Xu, Linfeng; Duan, Shuhui; Guo, Lihe; Fei, Jian

CORPORATE SOURCE: Institute of Biochemistry and Cell Biology Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS), Shanghai, Peop. Rep. China

SOURCE: Journal of Medicinal Chemistry (2006), 49(14), 4048-4051

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The dopamine transporter plays an important role in the mol. mechanism of cocaine dependence. It is suggested that inhibitors of the dopamine transporter would have strong therapeutic potential. Here we report that aromatic modification can constrain a linear peptide into the  $\beta$ -turn conformation, which is preferred by the dopamine transporter. On the basis of this finding, a novel selective and competitive peptidic inhibitor of the dopamine transporter was developed. The peptide binds to the dopamine- and cocaine-binding site of the dopamine transporter and has behavioral effects different from those of cocaine in mice.

IT 905306-49-2

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction)

RN 905306-49-2 HCAPLUS


CN L-Threonine, 3-[1,1'-biphenyl]-4-yl-L-alanyl-3-(phenylmethyl)-L-tyrosyl-L-threonyl-L-prolyl-L-lysyl- (9CI) (CA INDEX NAME)

Updated Search



09890219

Absolute stereochemistry.



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 7 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:147517 HCAPLUS

DOCUMENT NUMBER: 140:418430

TITLE: The Y1 receptor subtype mediates the cardiovascular changes evoked by NPY administered into the posterior hypothalamic nucleus of conscious rat

AUTHOR(S): Martin, John R.

CORPORATE SOURCE: Kirksville College of Osteopathic Medicine, Department of Pharmacology, A.T. Still University of Health Sciences, Kirksville, MO, 63501, USA

SOURCE: Brain Research (2004), 1002(1,2), 11-20

CODEN: BRREAP; ISSN: 0006-8993

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB An earlier study showed that the neuropeptide Y (NPY) receptor antagonist PYX-2 blocks the enhancement of a carbachol (CCh)-evoked pressor response produced by prior NPY administration into the posterior hypothalamic nucleus (PHN). The Y receptor subtype that mediates this response, and an increase in mean arterial pressure (MAP) and heart rate, remained unknown due to the lack of selectivity of PYX-2 for the Y receptor subtypes. Thus, the present study was undertaken to elucidate the Y receptor subtype responsible for mediating the NPY-evoked cardiovascular responses from the PHN by determining the rank order of potency of several NPY-related peptides

for

increasing MAP, and by correlating the pressor response evoked by these peptides to reported  $K_i$ 's and  $IC_{50}$ 's for the Y1, Y2, Y4 and Y5 receptor subtypes. The pharmacol. profile ( $YYY \geq NPY \geq [Leu^{31}, Pro^{34}]NPY \geq NPY_{13-36} \geq hPP$ ) and correlations suggest that the Y1 and/or Y5 receptor subtypes mediate these cardiovascular changes. Administration of the relatively non-selective Y

Updated Search

receptor antagonist PYX-2 or the selective Y1 receptor antagonist BIBP 3226 into the PHN prior to NPY completely blocked the cardiovascular responses. BIBP 3226 also blocked the cardiovascular changes evoked by [Leu31,Pro34]NPY, NPY13-36 and human pancreatic polypeptide (hPP). In contrast, neither BIBP 3226 nor PYX-2 inhibited the cardiovascular changes induced by peptide YY (PYY) or CCh microinjection into the PHN. These results show that NPY and PYY act on different receptors to mediate their resp. cardiovascular changes from the PHN with NPY stimulating the Y1 receptor.

IT 146999-93-1, PYX-2

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); BIOL (Biological study)


(NPY Y1 receptor subtype mediates cardiovascular changes evoked by NPY administered into posterior hypothalamic nucleus of conscious rat)

RN 146999-93-1 HCAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





09890219

REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 8 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:484863 HCAPLUS  
DOCUMENT NUMBER: 137:47448  
TITLE: Preparation of substituted phenylalaninol derivatives  
as protein tyrosine phosphatase inhibitors  
INVENTOR(S): Larsen, Scott D.; May, Paul D.; Bleasdale, John E.;  
Liljebris, Charlotta; Schostarez, Heinrich Josef;  
Barf, Tjeerd; Nilsson, Marianne  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S., 144 pp., Cont.-in-part of U.S. Ser. No. 138,642.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6410585	B1	20020625	US 1999-265410	19990310
US 6353023	B1	20020305	US 1998-138642	19980824
CA 2366308	A1	20000914	CA 2000-2366308	20000309
WO 2000053583	A1	20000914	WO 2000-US6022	20000309
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1161421	A1	20011212	EP 2000-917793	20000309
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
JP 2002539115	T	20021119	JP 2000-604023	20000309
AU 769511	B2	20040129	AU 2000-38711	20000309
PRIORITY APPLN. INFO.:			US 1997-57730P	P 19970828
			US 1998-138642	A2 19980824
			US 1999-265410	A 19990310
			WO 2000-US6022	W 20000309

OTHER SOURCE(S): MARPAT 137:47448  
GI




AB The invention comprises phenylalaninol derivs., e.g., I [R1 = OSO3H, OCH(CO2R5)2, OCH2CO2R5, OCH(CO2R5)CH2CO2R5, OC(CO2R5):CHCO2R5, CH2CH(CO2R5)2, CH:C(CO2R5)2, OCH2CONHOH, N(CH2CO2R5)2, OCHFCO2R5 (R5 = H, alkyl, alkylphenyl); R2 = CHR7NHXR6, group Q (R6 = alkyl, alkyl-CONH2, alkyl-NHCO2R5, etc.; R7 = H, any group given for R6); R10 = H, CO2R5, CONHOH, 5-tetrazolyl, F, OCH2CO2R5], or their pharmaceutically acceptable salts, as small mol. weight, non-peptidic inhibitors of protein tyrosine phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of non-insulin dependent diabetes mellitus. Thus, 5-[(2S)-2-[[[(2S)-2-[(tert-butoxycarbonyl)amino]-3-phenylpropanoyl]amino]-3-hydroxypropyl]-2-(carboxymethoxy)benzoic acid (claimed compound) was prepared and showed 80% inhibition of protein tyrosine phosphatase 1B at a concentration of 10  $\mu$ M.

IT 221077-70-9P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of substituted phenylalanine derivs. as protein tyrosine phosphatase inhibitors)

RN 221077-70-9 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-3-(methoxycarbonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:131877 HCAPLUS

DOCUMENT NUMBER: 136:369971

TITLE: Chemical approaches to protein engineering 20: the transformation of coded amino acid tyrosine to pro-templates having metal uptake potential in peptide/protein segments

AUTHOR(S): Ranganathan, Subranania; Tamilarasu, Natarajan

CORPORATE SOURCE: Discovery Laboratory, Indian Institute of Chemical Technology, Hyderabad, 500 007, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (2001), 40B(11), 1081-1103  
 CODEN: IJSBDB; ISSN: 0376-4699

PUBLISHER: National Institute of Science Communication

DOCUMENT TYPE: Journal


LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 136:369971

AB From vantage of inorg. chemical, the inability of any of the coded amino acid side chains to carry metal ions should appear as a grave omission in the genetic code, particularly since, metallo-enzymes play a pivotal role in diverse facets of life processes. The ready transformation of the coded amino acid tyrosine to metal uptake systems forms the core of the present work. 3-Acetyl-tyrosine [Tyr(3-Ac)]- readily derived from tyrosine is amenable to normal protocols in peptide synthesis and offers ideal ligand dispositions to craft pro-templates. This aspect has been illustrated by three broad strategies. The reaction of Tyr(3-Ac) with AEH, the mono Schiff base of acetylacetone and ethylenediamine (EDA), yields the pro-templates II [Tyr(3-Ac)-AEH] which can also be conveniently assembled, in situ, from acetylacetone, EDA and Tyr(3-Ac). Tripeptide, where Tyr(3-Ac) is flanked by Ala and Ser has been prepared and pro-template formation demonstrated in a peptide environment. Thus, either by normal peptide synthesis or by insertion of peptides containing Tyr(3-Ac), active sites for metal uptake can be constructed, thereby, in principle, obviating the need for 50-70 residues normally required. Pro-templates for metal uptake can be readily crafted by cross linking of Tyr(3-Ac) with EDA. This has also been illustrated with Ala-Tyr(3-Ac)-Ser-OMe. Thus, peptides where Tyr(3-Ac) is placed at appropriate locations, with EDA, can provide conformationally restrained metal uptake systems. Conversely, the oxime of Tyr(3-Ac) as well as the Schiff bases with  $\beta$ -ethanolamine and Gly-OMe can bring together proximate residues by metal complexation. This aspect has been exptl. realized. The pro-templates from Tyr(3-Ac) [Schiff bases with AEH/EDA/ $\beta$ -ethanolamine/Gly-OMe/and oximes] readily take up Cu(II), Co(II), and Ni(II) to form stable, well defined templates. The EPR spectra of the Cu(II) templates are that for typical square planar complexes, although in few sterically crowded examples rhombohedral distortion was seen. The observed A and g parameters compared favorably with that reported for metalloproteins, with particular closeness to laccase. Cyclic voltammetric studies were complicated by incursion of ligand oxidation, although in two cases clear  $E^\circ$  values of 340 mV and 305 mV were obtained, which lie in the range reported for metallo-proteins. The Ni(II) templates exhibited the expected <sup>1</sup>H NMR profile; in one example, coordination with two water mols. was seen. The Co(II) templates exhibited typical d-d transition at .apprx.600 nm in the visible spectrum.

IT 158256-97-4P 158256-98-5P 158257-00-2P  
 158257-01-3P 221234-43-1P 221234-52-2P  
 221234-67-9P 221234-88-4P 221234-95-3P  
 221235-06-9P 221235-42-3P 221235-46-7P  
 221236-41-5P 221236-45-9P 221237-13-4P  
 422284-55-7P 422284-56-8P 422284-59-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation of metal-binding tripeptides using modified tyrosine units)  
 RN 158256-97-4 HCAPLUS  
 CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl-, methyl  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).


09890219



RN 158256-98-5 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 158257-00-2 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 158257-01-3 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Updated Search


09890219

Absolute stereochemistry.  
Double bond geometry unknown.



RN 221234-43-1 HCAPLUS  
CN L-Serine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-acetyl-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221234-52-2 HCAPLUS  
CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-[[2-[(1-methyl-3-oxobutylidene)amino]ethyl]imino]ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

Updated Search


09890219



RN 221234-67-9 HCAPLUS

CN L-Serine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 221234-88-4 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-seryl-3-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 221234-95-3 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-acetyl-, methyl ester


Updated Search



09890219

(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221235-06-9 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-[[2-[(1-methyl-3-oxobutylidene)amino]ethyl]imino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




RN 221235-42-3 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.




Updated Search

09890219

RN 221235-46-7 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-seryl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 221236-41-5 HCAPLUS

CN L-Tyrosine, 23,2'-3-[1,2-ethanediylbis(nitriloethylidyne)]bis[N-[(phenylmethoxy)carbonyl]-L-alanyl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



Updated Search

09890219


PAGE 2-A



RN 221236-45-9 HCAPLUS  
CN L-Tyrosine, 23,2'3-[1,2-ethanediylbis(nitriloethylidyne)]bis[N-  
[(phenylmethoxy)carbonyl]-L-seryl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




RN 221237-13-4 HCAPLUS  
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.

Updated Search


09890219



RN 422284-55-7 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-acetyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 422284-56-8 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-[1-[[2-[(1-methyl-3-oxobutylidene)amino]ethyl]imino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.





RN 422284-59-1 HCAPLUS

CN L-Serine, 23,2'3-[1,2-ethanediylbis(nitriloethylidyne)]bis[N-[(phenylmethoxy)carbonyl]-L-alanyl-L-tyrosyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry unknown.

Updated Search



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 10 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:645993 HCAPLUS

DOCUMENT NUMBER: 133:238324


TITLE: Preparation of tyrosine amides and analogs as protein

09890219

tyrosine phosphatase inhibitors  
 INVENTOR(S): Larsen, Scott D.; May, Paul D.; Bleasdale, John E.;  
 Liljebris, Charlotta; Schostarez, Heinrich Josef;  
 Barf, Tjeerd; Nilsson, Marianne  
 PATENT ASSIGNEE(S): Pharmacia and Upjohn AB, Swed.  
 SOURCE: PCT Int. Appl., 124 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053583	A1	20000914	WO 2000-US6022	20000309
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6410585	B1	20020625	US 1999-265410	19990310
CA 2366308	A1	20000914	CA 2000-2366308	20000309
EP 1161421	A1	20011212	EP 2000-917793	20000309
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002539115	T	20021119	JP 2000-604023	20000309
AU 769511	B2	20040129	AU 2000-38711	20000309
PRIORITY APPLN. INFO.:			US 1999-265410	A 19990310
			US 1997-57730P	P 19970828
			US 1998-138642	A2 19980824
			WO 2000-US6022	W 20000309

OTHER SOURCE(S): MARPAT 133:238324  
 GI



09890219


AB RZCH<sub>2</sub>CR<sub>1</sub>R<sub>2</sub>NHZ<sub>1</sub>R<sub>3</sub> [I; R = OSO<sub>3</sub>H, OCH<sub>2</sub>CO<sub>2</sub>R<sub>4</sub>, OCH<sub>2</sub>CONHOH, N(CH<sub>2</sub>CO<sub>2</sub>R<sub>4</sub>)<sub>2</sub>, etc.; R<sub>1</sub> = H, CH<sub>2</sub>OH, alkylcarbamoyl, etc.; R<sub>2</sub> = H or Me; R<sub>4</sub> = H or (phenyl)alkyl; Z = (un)substituted 1,4-phenylene; Z<sub>1</sub> = CO or SO<sub>2</sub>] were prepared. Thus, (S)-Me<sub>2</sub>CO<sub>2</sub>CNHCH(CO<sub>2</sub>H)CH<sub>2</sub>C<sub>6</sub>H<sub>3</sub>(OH)I-4,3 was amidated by Ph(CH<sub>2</sub>)<sub>4</sub>NH<sub>2</sub> and the product converted in 5 steps to title compound II. Data for biol. activity of I were given.

IT 221077-70-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of tyrosine amides and analogs as protein tyrosine phosphatase inhibitors)

RN 221077-70-9 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-3-(methoxycarbonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:380070 HCAPLUS

DOCUMENT NUMBER: 133:187602

TITLE: Examination of novel non-phosphorus-containing phosphotyrosyl mimetics against protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains

AUTHOR(S): Gao, Yang; Wu, Li; Luo, Juliet H.; Guo, Ribo; Yang, Dajun; Zhang, Zhong-Yin; Burke, Terrence R., Jr.

CORPORATE SOURCE: Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(9), 923-927

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Inhibitory potencies were compared of several mono- and dicarboxy-based pTyr mimetics in Grb2 SH2 domain vs. protein-tyrosine phosphatase-1B (PTP1B) assays. Although in both systems pTyr residues provide critical binding elements, significant differences in the manner of recognition

Updated Search

09890219

exist between the two. This is reflected in the current study, where marked variation in relative potencies was observed between the two systems. Of particular note was the poor potency of all monocarboxy-based pTyr mimetics against PTP1B when incorporated into a hexapeptide platform. The recently reported high PTP1B inhibitory potency of similar phenylphosphate mimicking moieties displayed in small mol., non-peptide structures, raises questions on the limitations of using peptides as platforms for pTyr mimetics in the discovery of small mol. inhibitors.

IT 288854-38-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(examination of novel non-phosphorus-containing phosphotyrosyl mimetics


against

protein-tyrosine phosphatase-1B and demonstration of differential affinities toward Grb2 SH2 domains)

RN 288854-38-6 HCAPLUS

CN L-Leucinamide, N-acetyl-L- $\alpha$ -aspartyl-L-alanyl-L- $\alpha$ -aspartyl-L- $\alpha$ -glutamyl-3-carboxy-L-tyrosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 12 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:184222 HCAPLUS

DOCUMENT NUMBER: 130:223585

TITLE: Preparation of substituted phenylalanine derivatives as protein tyrosine phosphatase inhibitors

INVENTOR(S): Larsen, Scott D.; May, Paul D.; Bleasdale, John; Liljebris, Charlotta; Schostarez, Heinrich Josef; Barf, Tjeerd

PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA

SOURCE: PCT Int. Appl., 182 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3



Updated Search



09890219


PATENT INFORMATION:

PATENT NO.		KIND	DATE	APPLICATION NO.		DATE
WO 9911606		A2	19990311	WO 1998-US17327		19980824
WO 9911606		A3	19990708			
W:		AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2298601		A1	19990311	CA 1998-2298601		19980824
AU 9892010		A	19990322	AU 1998-92010		19980824
AU 749132		B2	20020620			
EP 1019364		A2	20000719	EP 1998-944476		19980824
EP 1019364		B1	20040609			
R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2001514245		T	20010911	JP 2000-508647		19980824
AT 268750		T	20040615	AT 1998-944476		19980824
PRIORITY APPLN. INFO.:				US 1997-57730P		P 19970828
				WO 1998-US17327		W 19980824
OTHER SOURCE(S):		MARPAT 130:223585				
GI						



- AB The present invention comprises title compds. I and II [G1 = R2, NR8R4; G2 = H, CONHR3, CH2OH, CH:CHR3; R1 = OSO3H, OCH(CO2R5)2, OCH2CO2R5, OCH(CO2R5)CH2CO2R5, O(CO2R5):CHCO2R5, CH2CH(CO2R5)2, CH:C(CO2R5)2, OCH2CONHOH, N(CH2CO2R5)2, OCHFCO2R5; R2 = C1-10 alkyl, C3-8 cycloalkyl, C0-6 alkylphenyl each substituted with 0-2 CO2R5 groups or 0-1 CONH2 groups, CHR7NHXR6, group Q; R3 = (un)substituted C1-12 alkyl, C1-4 alkyl-C3-6 cycloalkyl, C2-12 alkenyl, C3-12 alkynyl, (un)substituted C0-10 alkyl(G3)n, CH(CONH2)-C1-12 alkyl; R4 = H, C1-18 alkyl, alkenyl, C0-6 alkyl-G3; R5 = H, C1-10 alkyl, C1-5 alkylphenyl; R6 = C1-10 alkyl, substituted C1-6 alkyl; R7 = H, substituted C1-6 alkyl; R8 = C0-6 alkyl-G3, CHR7CO2R5, CHR7CH2CO2R5, CHR7CONHCH2COR5; G3 = (un)substituted Ph, naphthyl, heterocyclyl; R10 = H, CO2R5, CONHOH, 5-tetrazolyl, F, OCH2CO2R5; R11 = H, Me; X = CO, SO2, CO2; n = 0-3; with provisos] and pharmaceutically acceptable salts thereof, as small mol. weight, non-peptidic inhibitors of protein tyrosine phosphatase 1 (PTP1) which are useful for the treatment and/or prevention of non-insulin dependent diabetes mellitus (NIDDM). Thus, O-alkylation of N-tert-butoxycarbonyltyramine with di-Et chloromalonate, followed by acidic deprotection, amidation with 4-benzoyl-N-tert-butoxycarbonyl-L-phenylalanine, acidic deprotection, and amidation with succinic anhydride, gave desired title compound III (PNU 176073). III showed 60% inhibition of protein tyrosine phosphatase 1B at a concentration of 10  $\mu$ M.
- IT 221077-70-9P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of substituted phenylalanine derivs. as protein tyrosine phosphatase inhibitors)
- RN 221077-70-9 HCAPLUS
- CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-phenylalanyl-3-(methoxycarbonyl)-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 13 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1999:114715 HCAPLUS  
 DOCUMENT NUMBER: 130:245617  
 TITLE: Protein Engineering: Design of Single-Residue-Anchored Metal-Uptake Systems  
 AUTHOR(S): Ranganathan, Subramania; Tamilarasu, Natarajan  
 CORPORATE SOURCE: Biomolecular Research Unit, Regional Research Laboratory, Trivandrum, 695 019, India

09890219

SOURCE: Inorganic Chemistry (1999), 38(5), 1019-1023  
CODEN: INOCAJ; ISSN: 0020-1669  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Ethylenediamine-acetylacetone mono-Schiff base (AEH), hydroxylamine hydrochloride and ethylenediamine readily condense with peptides having 3-acetyltyrosine side chains to templates having two types of structural profile with AEH, hydroxylamine hydrochloride and ethylenediamine requiring two peptide units. Oximes I (R = Bz, R1 = OMe; R = Boc-Ala, R1 = OMe, Ser-OMe) were prepared by the oximation of the corresponding 3-acetyltyrosine derivs. with hydroxylamine hydrochloride, whereas Schiff bases II and III (R, R1 = same) were prepared by treating the corresponding 3-acetyltyrosine derivs. with ethylenediamine-acetylacetone mono-Schiff base and ethylenediamine, resp. I, II and III were complexed with transition metals to give the corresponding complexes.


IT 158257-00-2P 158257-01-3P 221234-52-2P  
221234-67-9P 221234-80-6P 221235-06-9P  
221235-42-3P 221235-46-7P 221236-41-5P  
221236-45-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and complexation with transition metals)

RN 158257-00-2 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 158257-01-3 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

Updated Search


09890219



RN 221234-52-2 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-[[2-[(1-methyl-3-oxobutylidene)amino]ethyl]imino]ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 221234-67-9 HCAPLUS

CN L-Serine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




Updated Search

```


RN      221234-80-6   HCAPLUS
CN      L-Serine, 23,2'3-[1,2-ethanediylbis(nitriloethylidyne)]bis[N-[(1,1-
dimethylethoxy)carbonyl]-L-alanyl-L-tyrosyl-, dimethyl ester (9CI)  (CA
INDEX NAME)

```

PAGE 1-A



PAGE 1-B



PAGE 2-A


Updated Search

09890219

RN 221235-06-9 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-[[2-[(1-methyl-3-oxobutylidene)amino]ethyl]imino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 221235-42-3 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 221235-46-7 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-seryl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

Updated Search

09890219




RN 221236-41-5 HCAPLUS

CN L-Tyrosine, 23,2'3-[1,2-ethanediylbis(nitriloethylidyne)]bis[N-[(phenylmethoxy)carbonyl]-L-alanyl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A



RN 221236-45-9 HCAPLUS

CN L-Tyrosine, 23,2'3-[1,2-ethanediylbis(nitriloethylidyne)]bis[N-


Updated Search

09890219

[(phenylmethoxy)carbonyl]-L-seryl-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.

PAGE 1-A



PAGE 2-A




IT 158256-97-4P 158256-98-5P 221234-43-1P  
221234-88-4P 221234-95-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and coupling with hydroxylamine or ethylenediamine or  
acetylacetone-ethylenediamine Schiff base followed by complexation with  
transition metals)  
RN 158256-97-4 HCAPLUS  
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl-, methyl  
ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search




09890219



RN 158256-98-5 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 221234-43-1 HCAPLUS

CN L-Serine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-acetyl-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 221234-88-4 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-seryl-3-acetyl-, methyl ester (9CI) (CA INDEX NAME)

Updated Search

09890219


Absolute stereochemistry.



RN 221234-95-3 HCAPLUS

CN L-Tyrosine, N-[(phenylmethoxy)carbonyl]-L-alanyl-3-acetyl-, methyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 221237-13-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(reactant for preparation of acetyltyrosine oximes and Schiff bases and their transition metal complexes)

RN 221237-13-4 HCAPLUS

CN	L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl- (9CI)	(CA
	INDEX NAME)	

Absolute stereochemistry.



Updated Search

09890219

REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 14 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:296799 HCAPLUS

DOCUMENT NUMBER: 129:50028

ORIGINAL REFERENCE NO.: 129:10331a,10334a

TITLE: A comparison of actions of neuropeptide Y (NPY) agonists and antagonists at NPY Y1 and Y2 receptors in anesthetized rats

AUTHOR(S): Smith-White, M.; Moriarty, M. J.; Potter, E. K.

CORPORATE SOURCE: Prince of Wales Medical Research Institute, Sydney, 2031, Australia

SOURCE: Neuropeptides (Edinburgh) (1998), 32(2), 109-118

CODEN: NRPPDD; ISSN: 0143-4179

PUBLISHER: Churchill Livingstone

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The pancreatic polypeptide family includes three members, neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP), with sequence homol. between members and species varying from approx. 50 to 80%. Some of these peptides were compared in the mammalian cardiovascular system for activity mediated by actions on pre- (Y2) and post-junctional (Y1) NPY receptors. NPY and PYY, with sequence homol. of 67% have similar actions on Y1 and Y2 receptors. Rat pancreatic polypeptide (rPP) with sequence homol. of approx. 50% is inactive at both. This study reports that the chimeric peptide, hPP1-11/NPY12-36 and the truncated peptide NPY2-36 show similar activity to NPY mediated through both receptor types in vivo, while salmon PYY (sPYY), with 81% homol. to NPY, has improved potency at both receptor subtypes. NPY3-36 has equal activity with NPY on actions mediated through Y2 receptors, but significantly reduced activity mediated through Y1 receptors. Two NPY antagonists were also examined: PYX2 was inactive in vivo and 1229U91 showed potent, long-lasting activity on Y1 receptor-mediated effects.

IT 146999-93-1, PYX-2



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(neuropeptide Y agonists and antagonists at neuropeptide Y1 and Y2 receptors in anesthetized rats)

RN 146999-93-1 HCAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginy-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutaminy-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 15 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:414784 HCAPLUS

DOCUMENT NUMBER: 127:130543

ORIGINAL REFERENCE NO.: 127:25021a,25024a

TITLE: Toward antibody-directed enzyme prodrug therapy with the T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate

AUTHOR(S): Smith, Gary K.; Banks, Sheila; Blumenkopf, Todd A.; Cory, Michael; Humphreys, Joan; Laethem, Ronald M.; Miller, John; Moxham, Cary P.; Mullin, Robert; Ray, Paul H.; Walton, Leslie M.; Wolfe, Lawrence A., III  
CORPORATE SOURCE: Glaxo Wellcome Inc., Research Triangle Park, NC, 27709, USA

SOURCE: Journal of Biological Chemistry (1997), 272(25), 15804-15816

CODEN: JBCHA3; ISSN: 0021-9258

PUBLISHER: American Society for Biochemistry and Molecular

DOCUMENT TYPE: Biology  
Journal  
LANGUAGE: English

- AB Antibody-directed enzyme prodrug therapy (ADEPT) has the potential of greatly enhancing antitumor selectivity of cancer therapy by synthesizing chemotherapeutic agents selectively at tumor sites. This therapy is based upon targeting a prodrug-activating enzyme to a tumor by attaching the enzyme to a tumor-selective antibody and dosing the enzyme-antibody conjugate systemically. After the enzyme-antibody conjugate is localized to the tumor, the prodrug is then also dosed systemically, and the previously targeted enzyme converts it to the active drug selectively at the tumor. Unfortunately, most enzymes capable of this specific, tumor site generation of drugs are foreign to the human body and as such are expected to raise an immune response when injected, which will limit their repeated administration. The authors reasoned that with the power of crystallog., mol. modeling and site-directed mutagenesis, this problem could be addressed through the development of a human enzyme that is capable of catalyzing a reaction that is otherwise not carried out in the human body. This would then allow use of prodrugs that are otherwise stable in vivo but that are substrates for a tumor-targeted mutant human enzyme. The authors report here the first test of this concept using the human enzyme carboxypeptidase A1 (hCPA1) and prodrugs of methotrexate (MTX). Based upon a computer model of the human enzyme built from the well known crystal structure of bovine carboxypeptidase A, the authors have designed and synthesized novel bulky phenylalanine- and tyrosine-based prodrugs of MTX that are metabolically stable in vivo and are not substrates for wild type human carboxypeptidases A. Two of these analogs are MTX- $\alpha$ -3-cyclobutylphenylalanine and MTX- $\alpha$ -3-cyclopentyltyrosine. also based upon the computer model, the authors have designed and produced a mutant of human carboxypeptidase A1, changed at position 268 from the wild type threonine to a glycine (hCPA1-T268G). This novel enzyme is capable of using the in vivo stable prodrugs, which are not substrates for the wild type hCPA1, as efficiently as the wild type hCPA1 uses its best substrates (i.e. MTX- $\alpha$ -phenylalanine). Thus, the  $k_{cat}/K_m$  values for hCPA1 with MTX- $\alpha$ -phenylalanine is  $0.44 \mu\text{M}^{-1} \text{s}^{-1}$ , and  $k_{cat}/K_m$  values for hCPA1-T268G with MTX- $\alpha$ -3-cyclobutylphenylalanine and MTX- $\alpha$ -3-cyclopentyltyrosine are  $1.8$  and  $0.16 \mu\text{M}^{-1} \text{s}^{-1}$ , resp. The cytotoxic efficiency of hCPA1-T268G was tested in an in vitro ADEPT model. For this experiment, hCPA1-T268G was chemical conjugated to ING-1, an antibody that binds to the tumor antigen Ep-Cam, or to Campath-1H, an antibody that binds to the T and cell antigen CDw52. These conjugates were then incubated with HT-29 human colon adenocarcinoma cells (which express Ep-Cam but not the Campath 1H antigen) followed by incubation of the cells with the in vivo stable prodrugs. The results showed that the targeted ING-1:hCPA1-T268G conjugate produced excellent activation of the MTX prodrugs to kill HT-29 cells as efficiently as MTX itself. By contrast, the enzyme-Cam-path 1H conjugate was without effect. These data strongly support the feasibility of ADEPT using a mutated human enzyme with a single amino acid change.
- IT 167549-67-9, GW 3199 167551-08-8, GW 3335  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(toward antibody-directed enzyme prodrug therapy of cancer with T268G mutant of human carboxypeptidase A1 and novel in vivo stable prodrugs of methotrexate)


09890219

RN 167549-67-9 HCAPLUS


CN L-Tyrosine, N-[4-[[[(2,4-diamino-6-pteridiny)methyl]methylamino]benzoyl]-L-  
 $\alpha$ -glutamyl-3-carboxy- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 167551-08-8 HCAPLUS


CN L-Tyrosine, N-[4-[[[(2,4-diamino-6-pteridiny)methyl]methylamino]benzoyl]-L-  
 $\alpha$ -glutamyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Updated Search



L16 ANSWER 16 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:345720 HCAPLUS

DOCUMENT NUMBER: 127:50981

ORIGINAL REFERENCE NO.: 127:9733a,9736a

TITLE: Unexpected lability of cysteine acetamidomethyl thiol protecting group. Tyrosine ring alkylation and disulfide bond formation upon acidolysis

AUTHOR(S): Engebretsen, May; Agner, Erik; Sandosham, Jessie; Fischer, Peter M.

CORPORATE SOURCE: Nycomed Pharma AS, Oslo, Norway

SOURCE: Journal of Peptide Research (1997), 49(4), 341-346

CODEN: JPERFA; ISSN: 1397-002X

PUBLISHER: Munksgaard

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cleavage and deprotection of H-Asn-Gly-Gly-Cys(Acm)-Glu(OBu-t)-Gln-Tyr(Bu-t)-Cys(Acm)-Ser(Bu-t)-Asp(OBu-t)-[(p-alkoxy)benzyloxy polystyrene resin] (Acm = acetamidomethyl) using standard conditions with various trifluoroacetic acid-containing mixts. were found to result in partial removal of the ordinarily acid-stable S-Acm groups. Apart from the desired peptide H-Asn-Gly-Gly-Cys(Acm)-Glu-Gln-Tyr-Cys(Acm)-Ser-Asp-OH, a disulfide-cyclic peptide derivative was also isolated. The peptide resin cleavage led to another major byproduct where the tyrosine side chain had been alkylated by an Acm group in a position ortho to the phenolic function. The formation of both byproducts could be suppressed by carrying out the cleavage/deprotection step at higher dilution and by inclusion of scavengers such as phenol. Oxidation of H-Asn-Gly-Gly-Cys-Glu-Gln-Tyr-Cys-Ser-Asp-OH by Ellman's reagent gave an authentic sample of the disulfide-cyclic peptide.

IT 191155-91-6P


RL: BYP (Byproduct); PREP (Preparation)

(unexpected acid lability of the protecting group acetamidomethyl in cysteine-containing peptides)


RN 191155-91-6 HCAPLUS

CN L-Aspartic acid, L-asparaginylglycylglycyl-S-[(acetylamino)methyl]-L-cysteinyl-L- $\alpha$ -glutamyl-L-glutaminyl-3-[(acetylamino)methyl]-L-tyrosyl-S-[(acetylamino)methyl]-L-cysteinyl-L-seryl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



—NHAc

—NH<sub>2</sub>

REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:448613 HCAPLUS

DOCUMENT NUMBER: 125:133035

ORIGINAL REFERENCE NO.: 125:24653a, 24656a

TITLE: Characterization of the peptide binding requirements for the cloned human pancreatic polypeptide-preferring receptor

AUTHOR(S): Gehlert, Donald R.; Schober, Douglas A.; Beavers, Lisa; Gadski, Robert; Hoffman, James A.; Smiley, David



CORPORATE SOURCE: L.; Chance, Ronald E.; Lundell, Ingrid; Larhammar, Dan  
Lilly Res. Lab., Eli Lilly and Company, Indianapolis,  
IN, 46285, USA  
SOURCE: Molecular Pharmacology (1996), 50(1), 112-118  
CODEN: MOPMA3; ISSN: 0026-895X  
PUBLISHER: Williams & Wilkins  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB Traditionally, neuropeptide Y (NPY) receptors have been divided into Y1 and Y2 subtypes based on peptide pharmacol. and synaptic localization. Other receptor subtypes have been proposed based on preferences for NPY, peptide YY (PYY), or pancreatic polypeptide (PP). Recently, we discovered a novel human membrane of this receptor family exhibiting high affinity for PP and PYY. In the current study, we expressed a DNA clone encoding this human PP-preferring receptor [hPP1 (or Y4)] in Chinese hamster ovary cells and performed a peptide structure-activity study. [125I]pPYY bound to homogenates of hPP1-Chinese hamster ovary cells with a Kd of 0.064 nM and a Bmax of 244 fmol/mg protein. Human PP inhibited binding with a Ki of 0.023 nM, whereas human PYY (Ki = 0.31 nM) and human NPY (Ki = 12 nM) were significantly less potent. Rat, porcine, and bovine PP inhibited binding with similar affinities to human PP, whereas avian PP was substantially less potent (Ki = 1 nM). Deletion of the first four amino acids reduced the affinity of bovine PP to 1 nM. Carboxyl-terminal fragments of NPY and PYY also had reduced potency compared with the native peptides. In addition, deletion of Tyr36-amide produced a substantial reduction



in affinity. Pro34-substituted NPY and PYY had modestly increased affinity compared with the native peptides, although Gln34-bPP had similar affinity compared with bovine PP. The carboxyl-terminally derived Y1 antagonist 1229U91 was a very potent (Ki = 0.042 nM) inhibitor of binding to hPP1. Thus, the carboxyl-terminal region of PP seems to be the most important part of the peptide for high affinity binding to hPP1. A few key residues (amino acids 2 and 3) in the amino-terminal region of PP contribute to the high affinity of the native peptide. Thus, features required for peptide recognition by the hPP1 receptor seem to be distinct from the Y1 and Y2 receptor.

IT 146999-93-1  
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
(peptide binding domain characterization in cloned human pancreatic polypeptide-preferring receptor)

RN 146999-93-1 HCAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutaminy-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 18 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:80798 HCAPLUS

DOCUMENT NUMBER: 124:233124

ORIGINAL REFERENCE NO.: 124:43215a, 43218a

TITLE: Syntheses of fluoroalkyl derivatives of two biologically active oligopeptides

AUTHOR(S): Li, Rui-Qing; Huang, Wei-Yuan

CORPORATE SOURCE: Shanghai Inst. Org. Chem., Chinese Acad. Sci., Shanghai, 200032, Peop. Rep. China

SOURCE: Chinese Journal of Chemistry (1995), 13(6), 558-64  
CODEN: CJOCEV; ISSN: 1001-604X

PUBLISHER: Science Press

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Fluoroalkyl derivs. of two biol. active oligopeptides, [(m-CF<sub>3</sub>)Tyr1]-Leu-enkephalin, [(m-CF<sub>2</sub>CF<sub>2</sub>Cl)Tyr1]-Leu-enkephalin, and [(m-COCF<sub>2</sub>Cl)Tyr2]-MSH releasing hormone have been synthesized. Studies on the activities of these peptides are underway.

09890219


IT 174748-41-5P 174748-42-6P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of fluoroalkyl enkephalin and MSH releasing hormone derivs.)  
RN 174748-41-5 HCAPLUS  
CN L-Asparagine, N2-[N2-[N-[3-(chlorodifluoroacetyl)-N-[N-[(1,1-  
dimethylethoxy)carbonyl]-S-(phenylmethyl)-L-cysteinyl]-L-tyrosyl]-L-  
isoleucyl]-L-glutaminyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 174748-42-6 HCAPLUS  
CN L-Asparagine, N2-[N2-[N-[3-(chlorodifluoroacetyl)-N-[S-(phenylmethyl)-L-  
cysteinyl]-L-tyrosyl]-L-isoleucyl]-L-glutaminyl]-, phenylmethyl ester  
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




Updated Search

09890219

IT 174748-43-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of fluoroalkyl enkephalin and MSH releasing hormone derivs.)  
RN 174748-43-7 HCAPLUS  
CN L-Asparagine, N2-[N2-[N-[3-(chlorodifluoroacetyl)-N-L-cysteiny]-L-tyrosyl]-L-isoleucyl]-L-glutaminy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L16 ANSWER 19 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:56084 HCAPLUS

DOCUMENT NUMBER: 124:117998

ORIGINAL REFERENCE NO.: 124:22004h, 22005a

TITLE: Preparation of cyclopeptide amides having serum calcium-lowering activity

INVENTOR(S): Kuzuki, Shigeo; Sato, Hirotoshi; Yamada, Hitoshi

PATENT ASSIGNEE(S): Asahi Chemical Ind, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 13 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
JP 07228599	A	19950829	JP 1994-208543	19940901
PRIORITY APPLN. INFO.:			JP 1994-208543	A 19940901
			JP 1993-326507	19931224
OTHER SOURCE(S):	MARPAT	124:117998		
GI				

Updated Search




I



III


- AB Hypocalcemic cyclic peptide amides [I; A<sup>1</sup>, A<sup>3</sup> = D- or L-Ser; A<sup>2</sup> = Asn, Asp; A<sup>4</sup>, A<sup>7</sup> = Lys, Lys(Ac); A<sup>5</sup> = D- or L-Leu, D-Leu-Lys-Leu-Ser-Gln-Glu; A<sup>6</sup> = His, His(Me); A<sup>8</sup> = Tyr, 3-(3,5-dichlorobenzyl)-Tyr; A<sup>9</sup> = Asp, β-Asp; excluding the compound where A<sup>1</sup> = A<sup>9</sup> = Asp, A<sup>2</sup> = Asn, A<sup>3</sup> = Ser, A<sup>4</sup> = A<sup>7</sup> = Lys, A<sup>5</sup> = Leu, A<sup>6</sup> = His, A<sup>8</sup> = Tyr] are prepared Thus, I (A<sup>1</sup> = D-Ser, A<sup>2</sup> = Asn, A<sup>3</sup> = Ser, A<sup>4</sup> = A<sup>7</sup> = Lys, A<sup>5</sup> = Leu, A<sup>6</sup> = His, A<sup>8</sup> = Tyr, A<sup>9</sup> = Asp) (II) was prepared by the solid phase method which involved coupling of a cyclopeptide fragment (III) with H-Lys(Cl-Z)-Leu-Ser(Bzl)-Gln-Glu(OBzl)-Leu-His-Lys(Cl-Z)-Leu-Gln-Thr(Bzl)-Tyr(Cl<sub>2</sub>Bzl)-Pro-Arg(Tos)-Thr(Bzl)-Asp(OBzl)-Val-Gly-Ala-Gly-Thr(Bzl)-Pro-MBHA resin (wherein Cl-Z = o-chlorobenzylloxycarbonyl, Cl<sub>2</sub>Bzl = 2,6-dichlorobenzyl, Tos = tosyl) (preparation given) using HOBt and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in a mixture of DMF and N-methylpyrrolidone followed by resin-cleavage and deprotection with HF(1) and anisole and chromatog. purification on a column of Dowex 1+2. III was 27.9-fold more potent than human calcitonin for lowering the serum Ca level in rats.
- IT 172733-69-6P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of cyclopeptide amides having serum calcium-lowering activity)
- RN 172733-69-6 HCAPLUS
- CN 1,7-Dicarbacalcitonin (eel), 1-butanoic acid-22-[3-[(3,5-dichlorophenyl)methyl]-L-tyrosine]- (9CI) (CA INDEX NAME)

PAGE 1-A





09890219


PAGE 1-B



PAGE 2-A




PAGE 2-B



Updated Search

C1



L16 ANSWER 20 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:933848 HCAPLUS

DOCUMENT NUMBER: 124:1276

ORIGINAL REFERENCE NO.: 124:287a,290a

TITLE: Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens

AUTHOR(S): Palea, S.; Corsi, M.; Rimland, J. M.; Trist, D. G.; Ratti, E.

CORPORATE SOURCE: Pharmacology Department, Glaxo Research Laboratories, Verona, 37135, Italy

SOURCE: British Journal of Pharmacology (1995), 116(5), 2401-6  
CODEN: BJPCBM; ISSN: 0007-1188

PUBLISHER: Stockton

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The pharmacol. activity of neuropeptide Y (NPY) and some analogs in inhibiting the twitch contractions induced by elec. stimulation (single pulses at 25 V, 0.15 Hz, 1 ms) in the prostatic portion of the rat isolated vas deferens was investigated. The rank order of agonist potency was: PYY > NPY2-36 > NPY » NPY13-36 » NPY18-36 »

[Leu31,Pro34]NPY = hPP, which is consistent with the activation of a Y2 receptor. The putative Y1 and Y2 antagonist, benextramine (BXT), incubated at 100  $\mu$ M for 10 or 60 min, was ineffective against PYY-induced inhibition of the twitch response. The putative NPY antagonist, PYX-2, incubated at 1  $\mu$ M for 20 min, was completely ineffective in antagonizing PYY-induced inhibition of twitches. The twitch response was totally inhibited by suramin (100  $\mu$ M) but was little affected by prazosin (1  $\mu$ M). Furthermore, NPY was without effect on the dose-response curve to ATP in resting conditions. Taken together, these results suggest that in our paradigm, NPY inhibits the release of a purinergic neurotransmitter which mediates contraction of the prostatic portion of the rat vas deferens.

IT 146999-93-1, PYX 2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(failure of putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in prostatic vas deferens)

RN 146999-93-1 HCAPLUS


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A







L16 ANSWER 21 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:784968 HCAPLUS

DOCUMENT NUMBER: 123:208783

ORIGINAL REFERENCE NO.: 123:36991a, 36994a

TITLE: Improvement of antibody-directed enzyme prodrug therapy (ADEPT)

INVENTOR(S): Smith, Gary Keith; Blumenkopf, Todd Andrew; Cory, Michael

PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK

SOURCE: PCT Int. Appl., 247 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9513095	A2	19950518	WO 1994-GB2483	19941111
WO 9513095	A3	19950713		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2176024	A1	19950518	CA 1994-2176024	19941111
AU 9481488	A	19950529	AU 1994-81488	19941111
AU 688412	B2	19980312		
ZA 9408987	A	19960513	ZA 1994-8987	19941111
EP 728018	A1	19960828	EP 1995-900827	19941111
EP 728018	B1	20030806		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 09507834	T	19970812	JP 1994-513695	19941111
AT 246516	T	20030815	AT 1995-900827	19941111
ES 2204935	T3	20040501	ES 1995-900827	19941111
US 6140100	A	20001031	US 1996-640906	19960509
US 6319702	B1	20011120	US 1999-395936	19990914

09890219

PRIORITY APPLN. INFO.:

GB 1993-23429	A 19931112
WO 1994-GB2483	W 19941111
US 1996-640906	A1 19960509

OTHER SOURCE(S): MARPAT 123:208783

AB The present invention relates to improvements in targetted enzyme prodrug therapy including antibody-directed enzyme prodrug therapy (ADEPT); it particularly relates to novel enzymes and prodrugs for use in ADEPT. Enzymes are targetted to specific tissues; prodrugs located at the site are converted into cytotoxic products. Thus, a single conjugate could generate a proportionately larger amount of cytotoxic drug at the target site (by repeated rounds of enzymatic catalysis of prodrug activation) than would occur in targetting of the prodrug itself. The enzyme used should be a mutant capable of catalyzing the conversion of the prodrug into the active cytotoxin, and the prodrug should be refractory to endogenous catalysis by the wild-type form of the enzyme. Thus, the  $k_{cat}/K_m$  value with wild-type human carboxypeptidase A1 for N-(4-(((2,4-diamino-6-pteridiny)methyl)methylamino)benzoyl)-L-glutamyl-3tert-butyl-L-phenylalanine was not measurable, but with a mutant (268 Thr→Gly) carboxypeptidase A1 the prodrug became an excellent substrate.

IT 167551-08-8P


RL: BPR (Biological process); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(improvement of antibody-directed enzyme prodrug therapy (ADEPT))


RN 167551-08-8 HCAPLUS

CN L-Tyrosine, N-[4-[[[(2,4-diamino-6-pteridiny)methyl]methylamino]benzoyl]-L- $\alpha$ -glutamyl-3-(1,1-dimethylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






IT 167549-59-9P 167549-60-2P 167549-61-3P  
 167549-62-4P 167549-64-6P 167549-65-7P  
 167549-66-8P 167549-67-9P 167551-05-5P  
 167551-06-6P 167551-07-7P 167551-13-5P  
 167551-15-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (improvement of antibody-directed enzyme prodrug therapy (ADEPT))

RN 167549-59-9 HCAPLUS

CN L-Tyrosine, 3-(methoxycarbonyl)-N-[N-[(phenylmethoxy)carbonyl]-L- $\alpha$ -  
 glutamyl]-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167549-60-2 HCAPLUS

CN L-Tyrosine, N-L- $\alpha$ -glutamyl-3-(methoxycarbonyl)-, dimethyl ester  
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

09890219




RN 167549-61-3 HCAPLUS

CN L-Tyrosine, N-[N-[4-[[[(1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino]-2-fluorobenzoyl]-L-α-glutamyl]-3-(methoxycarbonyl)-, dimethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



Updated Search

09890219

PAGE 2-A




RN 167549-62-4 HCAPLUS


CN L-Tyrosine, 3-carboxy-N-[N-[4-[[ (1,2-dihydro-3-methyl-1-oxobenzo[f]quinazolin-9-yl)methyl]amino]-2-fluorobenzoyl]-L- $\alpha$ -glutamyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




Updated Search




RN 167549-64-6 HCAPLUS  
 CN L-Tyrosine, 3-[(1,1-dimethylethoxy)carbonyl]-N-[N-  
 [(phenylmethoxy)carbonyl]-L- $\alpha$ -glutamyl]-, bis(1,1-dimethylethyl)  
 ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 167549-65-7 HCAPLUS  
 CN L-Tyrosine, 3-[(1,1-dimethylethoxy)carbonyl]-N-L- $\alpha$ -glutamyl-,  
 bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167549-66-8 HCAPLUS  
 CN L-Tyrosine, N-[N-[4-[(2,4-diamino-6-  
 pteridinyl)methyl]methylamino]benzoyl]-L- $\alpha$ -glutamyl]-3-[(1,1-

09890219


dimethylethoxy)carbonyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





RN 167549-67-9 HCAPLUS

CN L-Tyrosine, N-[4-[[[(2,4-diamino-6-pteridiny)l)methyl]methylamino]benzoyl]-L- $\alpha$ -glutamyl-3-carboxy- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Updated Search



RN 167551-05-5 HCAPLUS  
 CN L-Tyrosine, 3-(1,1-dimethylethyl)-N-[N-[(phenylmethoxy)carbonyl]-L- $\alpha$ -glutamyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 167551-06-6 HCAPLUS  
 CN L-Tyrosine, 3-(1,1-dimethylethyl)-N-L- $\alpha$ -glutamyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




09890219




RN 167551-07-7 HCAPLUS  
CN L-Tyrosine, N-[N-[4-[[ (2,4-diamino-6-  
pteridiny]methyl)methylamino]benzoyl]-L- $\alpha$ -glutamyl]-3-(1,1-  
dimethylethyl)-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 167551-13-5 HCAPLUS  
CN L-Tyrosine, N-L- $\alpha$ -glutamyl-3-(methoxycarbonyl)-, dimethyl ester,

Updated Search

09890219

monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 167551-15-7 HCAPLUS

CN L-Tyrosine, 3-[(1,1-dimethylethoxy)carbonyl]-N-L-α-glutamyl-,  
bis(1,1-dimethylethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

L16 ANSWER 22 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:177456 HCAPLUS

DOCUMENT NUMBER: 122:204915

ORIGINAL REFERENCE NO.: 122:37149a,37152a

TITLE: Putative neuropeptide Y antagonist failed to decrease  
overeating in obese Zucker rats

AUTHOR(S): Beck, Bernard; Stricker-Krongrad, Alain; Musse,  
Nadine; Nicolas, Jean-Pierre; Burlet, Claude

CORPORATE SOURCE: INSERM U.308, Mecanismes de Regulation du Comportement  
Alimentaire, 38 rue Lionnois, Nancy, 54000, Fr.

SOURCE: Neuroscience Letters (1994), 181(1-2), 126-8

Updated Search

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A central dysregulation of several neuropeptides could be at the origin of the marked hyperphagia of the obese Zucker rat, a well-known animal model used for the study of obesity. Neuropeptide Y (NPY), which stimulates food intake and increases early in life in obese rats, plays a major role in the development of this hyperphagia. The aim of our experiment was to test a proposed NPY antagonist namely PYX-2 in obese hyperphagic Zucker rats to know if it could be an interesting drug for limiting their food intakes. Four doses of PYX-2 (50-1000 pmol) were injected in a counterbalanced order in the lateral brain ventricles of 10 adult male Zucker rats. Food intake was recorded 0.5, 1, 2, 3, 6, and 23 h after PYX-2 injection and compared either to the rat's spontaneous food intake or to the food intake following injection of artificial CSF (vehicle) only. It was not modified by any dose of PYX-2 whatever the time considered (1 h after injection: 4.3 (1000 pmol) vs. 4.6 g; 23 h period: 27.0 (1000 pmol) vs. 26.6 g; N.S.). Thus, PYX-2, the putative NPY antagonist, totally failed to inhibit food intake in the obese rats. The absence of effect of PYX-2 on food intake can be explained by the structure of PYX-2, a modified 27-36 amino acid sequence that may not be recognized by the Y1-type NPY receptors which are involved in the regulation of feeding behavior.

IT 146999-93-1, PYX-2

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)


(putative neuropeptide Y antagonist PYX-2 failed to decrease overeating in obese Zucker rats)


RN 146999-93-1 HCAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L16 ANSWER 23 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:631312 HCAPLUS

DOCUMENT NUMBER: 121:231312

ORIGINAL REFERENCE NO.: 121:42203a,42206a

TITLE: The crafting of peptide segments with CuII uptake potential

AUTHOR(S): Ranganathan, Subramania; Tamilarasu, Natarajan

CORPORATE SOURCE: Dep. Chem., Indian Inst. Technol., Kanpur, 208 016, India

SOURCE: Tetrahedron Letters (1994), 35(3), 447-50


CODEN: TELEAY; ISSN: 0040-4039

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 121:231312

GI



AB Ethylenediamine-acetylacetone mono-Schiff base (AEH) and hydroxylamine hydrochloride readily condense with peptides having 3-acetyltyrosine side chains to templates having two types of structural profile with AEH having independent CuII uptake potential and with hydroxylamine hydrochloride requiring two peptide units. Oximes I (R = Bz, R1 = OMe; R = Boc-Ala, R1 = OMe, Ser-OMe) were prepared by the oximation of the corresponding 3-acetyltyrosine derivs. with hydroxylamine hydrochloride, whereas Schiff bases II (R, R1 = same) were prepared by treating the corresponding 3-acetyltyrosine derivs. with ethylenediamine-acetylacetone mono-Schiff base. I and II were complexed with Cu(OAc)<sub>2</sub> to give copper complexes III and IV, resp.

IT 158257-00-2P 158257-01-3P 158257-03-5P  
158257-04-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and complexation of, with copper)

RN 158257-00-2 HCAPLUS

CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.


09890219



RN 158257-01-3 HCAPLUS

CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-[1-(hydroxyimino)ethyl]-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry unknown.



RN 158257-03-5 HCAPLUS

CN L-Tyrosine, N-[N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl]-3-[1-[[2-[(3-hydroxy-1-methyl-2-butenylidene)amino]ethyl]imino]ethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.




RN 158257-04-6 HCAPLUS

Updated Search

09890219


CN L-Serine, N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl]-3-[1-[[2-[(3-hydroxy-1-methyl-2-butenylidene)amino]ethyl]imino]ethyl]-L-tyrosyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.  
Double bond geometry unknown.



IT 158256-97-4P 158256-98-5P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and oximation of)  
RN 158256-97-4 HCAPLUS  
CN L-Tyrosine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 158256-98-5 HCAPLUS  
CN L-Serine, N-[(1,1-dimethylethoxy)carbonyl]-L-alanyl-3-acetyl-L-tyrosyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).

Updated Search



L16 ANSWER 24 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:290690 HCAPLUS

DOCUMENT NUMBER: 120:290690

ORIGINAL REFERENCE NO.: 120:51027a, 51030a

TITLE: Inhibitory effect of neuropeptide Y and its analogs on inositol 1,4,5-trisphosphate level in rat cardiomyocytes

AUTHOR(S): Xiang, Hong; Brown, John C.

CORPORATE SOURCE: Dep. Physiol., Univ. British Columbia, Vancouver, BC, V6T 1Z3, Can.

SOURCE: Receptors and Channels (1993), 1(4), 315-21

CODEN: RCHAE4; ISSN: 1060-6823

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A neg. inotropic effect of neuropeptide Y (NPY) in the mammalian heart has been reported. The mechanism(s) involved in the action of NPY in the heart is still unclear. Since D-myo-inositol 1,4,5-trisphosphate [Ins(1,4,5)P<sub>3</sub>] is known to be an important second messenger in the regulation of cardiac function, the authors carried out a study to investigate the status of Ins(1,4,5)P<sub>3</sub> levels in response to NPY stimulation in rat cardiomyocytes. The authors also studied the possible involvement of NPY receptor subtypes in Ins(1,4,5)P<sub>3</sub> formation. [Leu<sup>31</sup>,Pro<sup>34</sup>]NPY, NPY<sub>13-36</sub>, NPY and peptide YY (PYY) induced a concentration-dependent decrease in Ins(1,4,5)P<sub>3</sub> levels [measured with an Ins(1,4,5)P<sub>3</sub> protein binding assay kit] in rat cardiomyocytes, which was blocked by NPY antagonists NPY<sub>18-36</sub> or PYX-2. There is no difference in the inhibitory effect of NPY and PYY on Ins(1,4,5)P<sub>3</sub> formation. Furthermore, effects of NPY and its analogs were insensitive to pertussis toxin pretreatment. Two new and more specific Y<sub>2</sub> receptor agonists, [Ahx<sup>5-24</sup>]NPY and [Ahx<sup>5-24</sup>,γ-Glu<sup>2</sup>-ε-Lys<sup>30</sup>]NPY, produced similar effects as NPY<sub>13-36</sub> on Ins(1,4,5)P<sub>3</sub> formation. These observations indicate that Y<sub>1</sub> and Y<sub>2</sub> subtypes of NPY receptor in rat cardiomyocytes may be associated with Ins(1,4,5)P<sub>3</sub> formation through a pertussis-toxin-insensitive G<sub>q</sub> protein. The decreased Ins(1,4,5)P<sub>3</sub> formation may be implicated in the neg. inotropic effect of NPY in the heart.

IT 146999-93-1, PYX-2

RL: BIOL (Biological study)

(neuropeptide Y-inhibited inositol triphosphate formation in response to, in heart)

RN 146999-93-1 HCAPLUS




09890219


CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutamyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L16 ANSWER 25 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:184241 HCAPLUS

DOCUMENT NUMBER: 118:184241

ORIGINAL REFERENCE NO.: 118:31403a,31406a

TITLE: Blockade of natural and neuropeptide Y-induced carbohydrate feeding by a receptor antagonist PYX-2

AUTHOR(S): Leibowitz, Sarah F.; Xuereb, Mark; Kim, Taewan

CORPORATE SOURCE: Rockefeller Univ., New York, NY, 10021, USA

SOURCE: NeuroReport (1992), 3(11), 1023-6

CODEN: NERPEZ; ISSN: 0959-4965

DOCUMENT TYPE: Journal

LANGUAGE: English

Updated Search

AB Neuropeptide Y (NPY) injected into the paraventricular nucleus (PVN) of rats has a potent stimulatory effect specifically on carbohydrate intake. This study examined the behavioral effects of a newly synthesized NPY antagonist, PYX-2. After PVN injection of PYX-2 (50-900 pmoles) alone, a strong dose-dependent reduction in spontaneous carbohydrate intake at the onset of the dark cycle was observed in freely-feeding rats. Moreover, at even lower doses (12.5 and 25.0 pmoles), PYX-2 also blocked the stimulatory action of PVN NPY (100 pmoles) on carbohydrate ingestion. These results provide the first evidence for the existence of endogenous NPY receptors in mediating the action of exogenous NPY in the hypothalamus. They also constitute a crucial step in demonstrating a physiol. function of these PVN NPY receptors specifically in controlling carbohydrate ingestion at the onset of the natural feeding cycle.

IT 146999-93-1

RL: BIOL (Biological study)


(carbohydrate appetite suppression by paraventricular nucleus administration of)


RN 146999-93-1 HCAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutaminy-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L16 ANSWER 26 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:207925 HCAPLUS

DOCUMENT NUMBER: 116:207925

ORIGINAL REFERENCE NO.: 116:35027a,35030a

TITLE: Synthesis of receptor antagonists of neuropeptide Y

AUTHOR(S): Tatemoto, Kazuhiko; Mann, Michael J.; Shimizu, Meikyo

CORPORATE SOURCE: Sch. Med., Stanford Univ., Stanford, CA, 94305, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (1992), 89(4), 1174-8

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The authors report the synthesis of receptor antagonists of neuropeptide Y (NPY) by a strategy based on synthesis of mixts. of analogs and the subsequent isolation and identification of receptor antagonists from these mixts. After screening a series of mixts. of NPY analogs by using an NPY antagonist assay, two potent receptor antagonists, designated PYX-1 and PYX-2, were isolated from an antagonist-containing mixture. The receptor antagonists inhibited release of intracellular calcium elicited by NPY in human erythroleukemia cells and displaced <sup>3</sup>H-labeled NPY from NPY receptors in rat brain membrane. The approach of screening and identifying useful analogs from synthetic mixts. may significantly reduce the time and resources previously required for development of receptor antagonists.



IT 146999-93-1P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and neuropeptide Y antagonist activity of)

RN 146999-93-1 HCAPLUS

CN L-Tyrosinamide, N-acetyl-3-[(2,6-dichlorophenyl)methyl]-L-tyrosyl-L-isoleucyl-L-asparaginyl-L-leucyl-L-isoleucyl-D-threonyl-L-arginyl-L-glutaminyl-L-arginyl-3-[(2,6-dichlorophenyl)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 27 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:805 HCAPLUS

DOCUMENT NUMBER: 112:805

ORIGINAL REFERENCE NO.: 112:151a,154a

TITLE: Changes in residues 1 and 4 of angiotensin II affect differently its agonist and tachyphylactic properties  
 AUTHOR(S): Shimuta, S. I.; Nakaie, C. R.; Paiva, A. C. M.;

CORPORATE SOURCE: Cordopatis, P.; Theodoropoulos, D.  
 Dep. Biophys., Esc. Paul. Med., Sao Paulo, BR-04034, Brazil

SOURCE: Naunyn-Schmiedeberg's Archives of Pharmacology (1989), 340(3), 309-13

CODEN: NSAPCC; ISSN: 0028-1298

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two series of angiotensin II analogs with modifications at positions 1 or 4 of the peptide chain were studied with respect to their tachyphylactic properties and to the kinetics of relaxation of the guinea-pig ileum after a contractile response to maximally effective concns. Tachyphylaxis was

measured by the decrease in response amplitude after 3 successive treatments (tachyphylactic index) and the relaxation rate was evaluated by the time taken for the tonus to reach half of its value at the moment of agonist washout (half relaxation time). A correlation between tachyphylactic index and half relaxation time was found for the series of position 1 analogs, but not for the position 4 analogs. For the 2 series, the half relaxation times of the tachyphylactic analogs decreased from the 1st to the 3rd of a series of successive treatments. Bulky substituents at position 1, which did not greatly affect the agonist activity, suppressed the tachyphylactic property. Evidently, the agonist and tachyphylactic properties of angiotensin II are due to its interaction resp., with an agonist site and a tachyphylaxis site on the receptor and the structural requirements for binding to the 2 sites are different.

IT 65143-30-8

RL: BIOL (Biological study)


(ileum relaxation and tachyphylaxis response to, mol. structure in relation to)



RN 65143-30-8 HCAPLUS

CN Angiotensin II, 4-[3-(phenylmethyl)-L-tyrosine]-5-L-isoleucine- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L16 ANSWER 28 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:46226 HCAPLUS

DOCUMENT NUMBER: 98:46226

ORIGINAL REFERENCE NO.: 98:6943a,6946a

TITLE: Direct detection of benzyltyrosine in peptides by mass spectrometry under pyrolysis conditions

AUTHOR(S): Kraft, Regine; Dettmer, Rudolf; Etzold, Gerhard

CORPORATE SOURCE: Cent. Inst. Mol. Biol., Ger. Acad. Sci., Berlin-Buch, DDR-1115, Ger. Dem. Rep.

SOURCE: Pept., Proc. Eur. Pept. Symp., 16th (1981), Meeting Date 1980, 694-9. Editor(s): Brunfeldt, K. Scriptor: Copenhagen, Den.

CODEN: 48NWA3

DOCUMENT TYPE: Conference

LANGUAGE: English

AB The sample was placed at the quartz tip of the direct insertion probe of the mass spectrometer and the temperature was increased stepwise from 250 to 300°. 3-Benzyltyrosine was detected by the high-intensity peak at m/z 197. Characteristic pyrolysis fragments in the mass spectra of the decapeptide Gn-RH and insulin heptapeptide B24-B20 and their 3-benzyltyrosine derivs. are given.

IT 84167-14-6



RL: ANST (Analytical study)

(benzyltyrosine detection in, by pyrolysis mass spectrometry)

RN 84167-14-6 HCAPLUS

CN Luteinizing hormone-releasing factor (swine), 5-[3-(phenylmethyl)-L-tyrosine]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L16 ANSWER 29 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1981:66004 HCAPLUS  
 DOCUMENT NUMBER: 94:66004  
 ORIGINAL REFERENCE NO.: 94:10781a,10784a  
 TITLE: NG-Mesitylene-2-sulfonylarginine  
 AUTHOR(S): Takeyama, Masaharu; Koyama, Kaname; Yajima, Haruaki

09890219

CORPORATE SOURCE: Fac. Pharm. Sci., Kyoto Univ., Kyoto, 606, Japan  
SOURCE: Peptide Chemistry (1979), Volume Date 1978, 16th, 1-4  
CODEN: PECHDP; ISSN: 0388-3698  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




AB R-Arg-OH [R = PhCH<sub>2</sub>O<sub>2</sub>C, Me<sub>3</sub>CO<sub>2</sub>C, p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>O<sub>2</sub>C [Z(OMe)]] were treated with Mts-Cl (Mts = mesitylene-2-sulfonyl) to give R-Arg(Mts)-OH, which were R-deblocked to give H-Arg(Mts)-OH (I). The Mts group of I was stable to CF<sub>3</sub>CO<sub>2</sub>H, 1N NaOH, 80% NH<sub>2</sub>NH<sub>2</sub>, and 1-hydroxybenzotriazole, but it was cleaved by HF, CH<sub>3</sub>SO<sub>3</sub>H (MSA), and CF<sub>3</sub>SO<sub>3</sub>H. Z(OMe)-Ile-Tyr-Arg(Mts)-OH (II) was cleaved by MSA/anisole to give H-Ile-Tyr-Arg-OH along with side products H-Tyr(Mts)-Arg-OH and peptide III. More efficient scavenger systems were treated for the deblocking of II by MSA; phenolic compds. (e.g., o-cresol) improved the suppression of the side reactions of the Mts group.

IT 76378-98-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as side product in deblocking of  
(mesitylenesulfonyl)arginine-containing tripeptide derivative)

RN 76378-98-8 HCAPLUS

CN L-Arginine, N2-[N-L-isoleucyl-3-[(4-methoxyphenyl)methyl]tyrosyl]- (9CI)  
(CA INDEX NAME)



Updated Search



09890219

L16 ANSWER 30 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1980:129313 HCAPLUS  
DOCUMENT NUMBER: 92:129313  
ORIGINAL REFERENCE NO.: 92:21107a,21110a  
TITLE: The synthesis of five heptapeptide analogs by the solid-phase technique. Side reactions of tyrosyl and glutamyl residues  
AUTHOR(S): Soerup, Per; Braae, Hanne; Villemoes, Preben; Christensen, Thorkild  
CORPORATE SOURCE: H. C. Oersted Inst., Univ. Copenhagen, Copenhagen, DK-2100, Den.  
SOURCE: Acta Chemica Scandinavica, Series B: Organic Chemistry and Biochemistry (1979), B33(9), 653-63  
CODEN: ACBOCV; ISSN: 0302-4369  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB H-Tyr-X-X1-X2-Ala-Ala-Gly-OH (X-X1-X2 = Glu-Glu-Tyr, Tyr-Glu-Glu, Glu-Tyr-Glu, Glu-Tyr-Tyr, Glu-Glu-Glu) were prepared by the solid-phase method using an automated synthesizer and coupling and  $\alpha$ -amino deblocking steps were monitored by potentiometric titrns. with perchloric acid. The formation of N-terminal pyroglutamyl peptide side products during coupling steps were followed by titration. Side products were also formed which contained 3-benzyltyrosine residues resulting from an O  $\rightarrow$  C rearrangement of O-benzyltyrosine residues during cleavage.


IT 73045-08-6P

RL: PRP (Properties); PREP (Preparation)  
(formation and mass spectrum of)

RN 73045-08-6 HCAPLUS

CN Glycine, N-[N-[N-[3-(phenylmethyl)-N-[N-(N-L-tyrosyl-L- $\alpha$ -glutamyl)]-L- $\alpha$ -glutamyl]-L-tyrosyl]-L-alanyl]-L-alanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 31 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:551723 HCAPLUS  
DOCUMENT NUMBER: 91:151723  
ORIGINAL REFERENCE NO.: 91:24369a,24372a  
TITLE: Angiotensin II analogs. 14. Roles of the imidazole

Updated Search

09890219

AUTHOR(S): nitrogens of position-6 histidine in pressor activity  
Hsieh, Kun-Hwa; Jorgensen, Eugene C.; Lee, Thomas C.  
CORPORATE SOURCE: Sch. Pharm., Univ. California, San Francisco, CA,  
94143, USA  
SOURCE: Journal of Medicinal Chemistry (1979), 22(10),  
1199-206  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English


AB Replacement of the position-6 histidine residue in [Asn1, Ile5]  
angiotensin II produced analogs with pressor activities in the rat  
(compared to [Asn1, Val5]angiotensin II [53-73-6] = 100%) as  
follows: 6-(2,4-diaminobutyric acid)- [60317-98-8], 0.02%;  
6-(4-nitrophenylalanine)- [71239-97-9], 0.02%;  
6-( $\beta$ -(2-imidazolyl)-D- $\alpha$ -alanine)- [71239-98-0], 0.04%;  
6-( $\beta$ -(2-pyridyl)-L- $\alpha$ -alanine)- [60317-99-9], 6.5%;  
6-( $\beta$ -(2-pyridyl)-D- $\alpha$ -alanine)- [60318-00-5], 0.4%. [Asn1,  
Tyr(6-Bzl)4, Ile5, Phe(1-NO2)6]angiotensin II [71262-84-5] was  
isolated as a side product in the HF-deprotection reaction and was shown  
to possess 0.03% pressor activity. Incorporation of the racemic  
N $\alpha$ -butyloxycarbonyl-Nim-benzyl- $\beta$ -(2-imidazolyl)-DL- $\alpha$ -  
alanine into the peptide and separation of the resultant diastereomeric  
angiotensin II by countercurrent distribution eliminated the need for the  
laborious resolution and protection of the L isomer, which might racemize  
extensively during peptide synthesis. Correlation of the chemical structures  
with biol. activities of position-6 analogs suggests that the heterocyclic  
N atoms of histidine are important for angiotensin II to be recognized by  
the receptor, and the pro-pyridine N of histidine plays a minor role and  
the tele-pyrrole N a major role in this interaction.

IT 71262-84-5P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and vasopressor activity of)


RN 71262-84-5 HCAPLUS

CN Angiotensin II, 1-L-asparagine-4-[3-(phenylmethyl)-L-tyrosine]-5-L-  
isoleucine-6-(4-nitro-L-phenylalanine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Updated Search



L16 ANSWER 32 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:502562 HCAPLUS

DOCUMENT NUMBER: 91:102562

ORIGINAL REFERENCE NO.: 91:16473a,16476a

TITLE: Angiotensin II analogs. 12. Role of the aromatic ring of position 8 phenylalanine in pressor activity

AUTHOR(S): Hsieh, Kun-Hwa; Jorgensen, Eugene C.; Lee, Thomas C.

CORPORATE SOURCE: Sch. Pharm., Univ. California, San Francisco, CA, 94143, USA

SOURCE: Journal of Medicinal Chemistry (1979), 22(9), 1038-44  
CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The relative contributions to pressor activity of lipophilic and aromatic character for the Ph ring of position 8 phenylalanine in [Asn<sup>1</sup>,Ile<sup>5</sup>]angiotensin II was evaluated by replacing the benzyl side chain with a variety of normal or branched aliphatic and substituted aromatic residues. A conformationally constrained analog in which the 2-aminoindane-2-carboxylic acid (Ind) [27473-62-7] replaced the phenylalanine residue was prepared to exam. the steric requirement for the aromatic ring for pressor activity. The analogs were synthesized by the solid-phase method and had the following pressor activities in the rat: aminoheptanoic acid<sup>8</sup> [60318-02-7], 11.5%; Nle<sup>8</sup> [60318-01-6], 7.3%; Leu<sup>8</sup> [38027-94-0], 1.2%; Ind<sup>8</sup> [71066-04-1], 0.1%; Phe(4-NH<sub>2</sub>)<sup>8</sup> [71066-07-4], 52.5%; Phe(4-NO<sub>2</sub>)<sup>8</sup> [71066-05-2], 15%; and the disubstituted analogs [Sar<sup>1</sup>,Ile<sup>5</sup>,Leu<sup>8</sup>]angiotensin II [38027-93-9], 2.5%; [des-Asp<sup>1</sup>,D-Ala<sup>2</sup>,Ile<sup>5</sup>,Leu<sup>8</sup>]angiotensin II [71066-03-0], 1.4%; [Asn,<sup>1</sup>Tyr(3-Bzl)<sup>4</sup>,Ile<sup>5</sup>,Phe(4-NO<sub>2</sub>)<sup>8</sup>]angiotensin II [70-47-3], 0.2%. In the absence of aromatic character, higher lipophilicity of the analogs resulted in higher pressor activity. However, aromaticity was more important than lipophilic character and was necessary for full activity. Steric interference, caused by a bulky substituent on the ring or by branching of the aliphatic residue, resulted in reduced potency. When the sizes of the substituents were comparable, the aromatic,  $\pi$ -electron-enriched analogs were more active than the  $\pi$ -electron-deficient analogs. The spatial orientation of the ring relative to the peptide backbone was critical for the pressor effect. The Ind<sup>8</sup> analog was essentially lacking in pressor activity and was more

09890219

potent than the Leu8 analog as an angiotensin II antagonist, in spite of its aromatic nature. The Sar1,Leu8 analog was more potent and longer acting than Ind8 analog as an angiotensin II inhibitor. Apparently incorporation of a conformationally constrained aromatic ring in position 8 of angiotensin analogs can be an effective approach to the development of potent inhibitors with low pressor activity.

IT 71066-06-3P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and vasopressor activity of)

RN 71066-06-3 HCAPLUS


CN Angiotensin II, 1-L-asparagine-4-[3-(phenylmethyl)-L-tyrosine]-5-L-isoleucine-8-(4-nitro-L-phenylalanine)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



Updated Search

09890219

L16 ANSWER 33 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1979:421016 HCAPLUS

DOCUMENT NUMBER: 91:21016

ORIGINAL REFERENCE NO.: 91:3533a,3536a

TITLE: Studies on peptides. LXXX.

NG-Mesitylene-2-sulfonylarginine

AUTHOR(S): Yajima, Haruaki; Takeyama, Masaharu; Kanaki, Jun;

Nishimura, Osamu; Fujino, Masahiko

CORPORATE SOURCE: Fac. Pharm. Sci., Kyoto Univ., Kyoto, Japan

SOURCE: Chemical & Pharmaceutical Bulletin (1978), 26(12),  
3752-7

CODEN: CPBTAL; ISSN: 0009-2363

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The title compound was prepared by treating Z(OMe)-Arg-OH [Z(OMe) = p-MeOC<sub>6</sub>H<sub>4</sub>CH<sub>2</sub>O<sub>2</sub>C] with Mts-Cl (Mts = mesitylene-2-sulfonyl) and Z(OMe)-deblocking the resulting Z(OMe)-Arg(Mts)-OH by HCl. The Mts group can be quant. cleaved by HF, MeSO<sub>3</sub>H, and CF<sub>3</sub>SO<sub>3</sub>H. During the cleavage of Mts from tyrosine-containing peptides, the phenolic OH groups were partially mesitylenesulfonylated as a side reaction. This side reaction can be suppressed by the addition of cation scavengers, e.g., anisole-thioanisole-cresol (1:1:1).


IT 70374-84-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 70374-84-4 HCAPLUS

CN L-Arginine, N2-[N-L-isoleucyl-3-(phenylmethyl)-L-tyrosyl]- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 34 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:45229 HCAPLUS

DOCUMENT NUMBER: 88:45229

ORIGINAL REFERENCE NO.: 88:7065a,7068a

TITLE: Effect of tyrosine ionization upon biological  
activities of angiotensin II and two new peptide  
analogs

AUTHOR(S): Nakaie, Clovis R.; Oshiro, Maria E. M.; Goissis,  
Gilberto; Paiva, Antonio C. M.

CORPORATE SOURCE: Dep. Biophys. Physiol., Esc. Paulista Med., Sao Paulo,  
Brazil

Updated Search

09890219

SOURCE: Biochimica et Biophysica Acta, Protein Structure  
(1977), 495(1), 151-8  
CODEN: BBPTBH; ISSN: 0005-2795

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The role of the tyrosine side-chain in the smooth muscle-contracting activity of angiotensin II [11128-99-7] was investigated by determining intrinsic activities and ED50 values of [4-(3-chlorotyrosine)]angiotensin II [65143-29-5] and [4-(3-benzyltyrosine)]angiotensin II [65143-30-8] in the isolated guinea-pig ileum and rat uterus. [4-(3-Chlorotyrosine)]angiotensin II activity was compared with that of angiotensin II at different pH values, in which the ratio of their degrees of phenolic ionization varied. Deprotonation of the phenolic group hindered binding to smooth muscle cell receptors, but not triggering of the response by the hormone receptor complex. Steric hindrance by the benzyl substituent in [4-(3-benzyltyrosine)]angiotensin II decreased both receptor-binding and triggering of the response.

IT 65143-30-8


RL: BIOL (Biological study)  
(biol. activity of angiotensin II in relation to)

RN 65143-30-8 HCAPLUS


CN Angiotensin II, 4-[3-(phenylmethyl)-L-tyrosine]-5-L-isoleucine- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



Updated Search




L16 ANSWER 35 OF 35 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 1976:508979 HCAPLUS  
 DOCUMENT NUMBER: 85:108979  
 ORIGINAL REFERENCE NO.: 85:17509a,17512a  
 TITLE: Solid-phase synthesis of a minimally protected peptide fragment for the synthesis of corticotropin. Synthesis of [Lys(Tfa)15,16,21]-ACTH-(15-24)-decapeptide  
 AUTHOR(S): Suzuki, Kenji; Nitta, Kazuo  
 CORPORATE SOURCE: Tohoku Coll. Pharm., Sendai, Japan  
 SOURCE: Annual Report of the Tohoku College of Pharmacy (1975), 22, 47-50  
 CODEN: TYKNAQ; ISSN: 0495-7342  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Japanese  
 AB The stepwise coupling of Me3CO2C blocked amino acids onto Me3CO2C-Pro-Resin, followed by the treatment with HF and subsequent CM-cellulose column chromatog. gave 34% title compound, Lys-Lys(Tfa)-Lys(Tfa)-Arg-Arg-Pro-Val-Lys(Tfa)-Val-Tyr-Pro (Tfa = COCF3), 13% depletion sequence, Lys-Lys(Tfa)-Lys(Tfa)-Arg-Pro-Val-Lys(Tfa)-Val-Tyr-Pro, and 5% damaged sequence, Lys(Lys(Tfa)-Lys(Tfa)-Arg-Arg-Pro-Val-Lys(Tfa)-Val-Tyr(CH2Ph)-Pro.  
 IT 60345-64-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)  
 RN 60345-64-4 HCAPLUS  
 CN L-Proline, 1-[N-[N-[N2-[N-[1-[N2-[N2-[N2-[N2-L-lysyl-N6-(trifluoroacetyl)-L-lysyl]-N6-(trifluoroacetyl)-L-lysyl]-L-arginyl]-L-arginyl]-L-prolyl]-L-valyl]-N6-(trifluoroacetyl)-L-lysyl]-L-valyl]-3-(phenylmethyl)-L-tyrosyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.







=> file caold  
COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
201.58	616.41
SINCE FILE	TOTAL
ENTRY	SESSION
-28.80	-32.80

FILE 'CAOLD' ENTERED AT 17:39:20 ON 03 NOV 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1907-1966  
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAOLD will be discontinued and removed from associated database clusters.

- . November 22, 2008 - removed from database clusters
- . December 31, 2008 - removed from STN

Updated Search

09890219

Content previously available only in CAOLD is now available in CA/CAPLUS. To learn more about the options available for transferring saved search queries and answer sets to CA/CAPLUS, contact your STN Service Center.

=> d his

(FILE 'HOME' ENTERED AT 17:23:26 ON 03 NOV 2008)

FILE 'REGISTRY' ENTERED AT 17:23:38 ON 03 NOV 2008

L1 STRUCTURE UPLOADED  
L2 5 S L1  
L3 728 S L1 FULL

FILE 'HCAPLUS' ENTERED AT 17:27:38 ON 03 NOV 2008

L4 47 S L3

FILE 'REGISTRY' ENTERED AT 17:27:44 ON 03 NOV 2008

L5 STRUCTURE UPLOADED  
L6 4 S L5  
L7 700 S L5 FULL  
L8 0 S L7 NOT L3

FILE 'HCAPLUS' ENTERED AT 17:33:10 ON 03 NOV 2008

L9 41 S L7  
L10 3 S L9 AND MATSUOKA, H?/AU  
L11 38 S L9 NOT L10  
L12 2 S L11 AND SATO, T?/AU

FILE 'HCAPLUS' ENTERED AT 17:37:53 ON 03 NOV 2008

L13 36 S L11 NOT L12  
L14 0 S L13 AND TAKAHASHI, T?/AU  
L15 1 S L13 AND KIM, D?/AU  
L16 35 S L13 NOT L15  
L17 0 S L16 AND JUNG, K?/AU  
L18 0 S L16 AND PARK, C?/AU

FILE 'CAOLD' ENTERED AT 17:39:20 ON 03 NOV 2008

=> s l3

L19 0 L3

Updated Search